name,title,description,pubmed_id,platform,platform_technology_type,feature_count,channel_count,sample_count,value_type,reference_series,order,file_location,num_L1000_genes,target_column,num_classes,class_distribution,class_mapping,is_train
GDS5027,"NeOAdjuvant Herceptin (NOAH) trial: formalin-fixed, paraffin-embedded breast cancer biopsies",Analysis of FFPE core biopsies from pre-treated patients with HER2+ breast cancer (BC) randomized to receive neoadjuvant chemotherapy only or chemotherapy+trastuzumab (herceptin). Results provide insight into the molecular basis of survival outcomes following trastuzumab-based chemotherapy.,24443618,GPL570,in situ oligonucleotide,54675,1,156,transformed count,GSE50948,none,data/GEO_v2/datasets/GDS5027.csv,958,genotype/variation,2,"{'HER2+': 114, 'HER2-': 42}","{'HER2+': 0, 'HER2-': 1}",True
GDS5027,"NeOAdjuvant Herceptin (NOAH) trial: formalin-fixed, paraffin-embedded breast cancer biopsies",Analysis of FFPE core biopsies from pre-treated patients with HER2+ breast cancer (BC) randomized to receive neoadjuvant chemotherapy only or chemotherapy+trastuzumab (herceptin). Results provide insight into the molecular basis of survival outcomes following trastuzumab-based chemotherapy.,24443618,GPL570,in situ oligonucleotide,54675,1,156,transformed count,GSE50948,none,data/GEO_v2/datasets/GDS5027.csv,958,protocol,2,"{'doxorubicin/paclitaxel + cyclophosphamide/methotrexate/fluorouracil': 93, 'doxorubicin/paclitaxel + cyclophosphamide/methotrexate/fluorouracil + trastuzumab': 63}","{'doxorubicin/paclitaxel + cyclophosphamide/methotrexate/fluorouracil': 0, 'doxorubicin/paclitaxel + cyclophosphamide/methotrexate/fluorouracil + trastuzumab': 1}",True
GDS5027,"NeOAdjuvant Herceptin (NOAH) trial: formalin-fixed, paraffin-embedded breast cancer biopsies",Analysis of FFPE core biopsies from pre-treated patients with HER2+ breast cancer (BC) randomized to receive neoadjuvant chemotherapy only or chemotherapy+trastuzumab (herceptin). Results provide insight into the molecular basis of survival outcomes following trastuzumab-based chemotherapy.,24443618,GPL570,in situ oligonucleotide,54675,1,156,transformed count,GSE50948,none,data/GEO_v2/datasets/GDS5027.csv,958,other,2,"{'response group: residual disease (RD)': 103, 'response group: pathohistologic complete remission (pCR)': 53}","{'response group: residual disease (RD)': 0, 'response group: pathohistologic complete remission (pCR)': 1}",True
GDS2767,Blood response to various beverages: time course,"Analysis of blood samples from 6 individuals at various time points up to 12 hours following the intake of water, ethanol, grape juice, or red wine. Results may contribute to elucidating the mechanisms underlying the cardioprotective effects of red wine.",17010189,GPL96,in situ oligonucleotide,22283,1,108,transformed count,GSE3846,none,data/GEO_v2/datasets/GDS2767.csv,958,agent,4,"{'water': 29, 'red wine': 28, 'grape juice': 26, 'alcohol': 25}","{'water': 0, 'red wine': 0, 'grape juice': 0, 'alcohol': 1}",True
GDS2767,Blood response to various beverages: time course,"Analysis of blood samples from 6 individuals at various time points up to 12 hours following the intake of water, ethanol, grape juice, or red wine. Results may contribute to elucidating the mechanisms underlying the cardioprotective effects of red wine.",17010189,GPL96,in situ oligonucleotide,22283,1,108,transformed count,GSE3846,none,data/GEO_v2/datasets/GDS2767.csv,958,agent,4,"{'water': 29, 'red wine': 28, 'grape juice': 26, 'alcohol': 25}","{'water': 0, 'red wine': 0, 'grape juice': 1, 'alcohol': 0}",True
GDS2767,Blood response to various beverages: time course,"Analysis of blood samples from 6 individuals at various time points up to 12 hours following the intake of water, ethanol, grape juice, or red wine. Results may contribute to elucidating the mechanisms underlying the cardioprotective effects of red wine.",17010189,GPL96,in situ oligonucleotide,22283,1,108,transformed count,GSE3846,none,data/GEO_v2/datasets/GDS2767.csv,958,agent,4,"{'water': 29, 'red wine': 28, 'grape juice': 26, 'alcohol': 25}","{'water': 0, 'red wine': 1, 'grape juice': 0, 'alcohol': 0}",True
GDS2767,Blood response to various beverages: time course,"Analysis of blood samples from 6 individuals at various time points up to 12 hours following the intake of water, ethanol, grape juice, or red wine. Results may contribute to elucidating the mechanisms underlying the cardioprotective effects of red wine.",17010189,GPL96,in situ oligonucleotide,22283,1,108,transformed count,GSE3846,none,data/GEO_v2/datasets/GDS2767.csv,958,agent,4,"{'water': 29, 'red wine': 28, 'grape juice': 26, 'alcohol': 25}","{'water': 1, 'red wine': 0, 'grape juice': 0, 'alcohol': 0}",True
GDS4182,WHO 2008-classified acute myeloid leukemia subgroups (Analysis II): bone marrow mononuclear cells,Analysis of BMMCs from untreated patients with AML-MRC (AML with myelodysplasia-related changes) and from the combined group AML-NOS plus AML-MLD-sole on the basis of cytogenetics or a myelodysplastic syndrome (MDS) history. Results provide insight into the relevance of MLD for AML classification.,20581309,GPL570,in situ oligonucleotide,54675,1,96,transformed count,GSE21261,none,data/GEO_v2/datasets/GDS4182.csv,958,disease state,2,"{'AML-multilineage dysplasia sole + AML-not otherwise specified (AML-MLD-sole + AML-NOS)': 80, 'AML-myelodysplasia related changes (AML-MRC)': 16}","{'AML-multilineage dysplasia sole + AML-not otherwise specified (AML-MLD-sole + AML-NOS)': 0, 'AML-myelodysplasia related changes (AML-MRC)': 1}",False
GDS5205,Long-term adult survivors of glioblastoma: primary tumors,"Analysis of primary tumors from glioblastoma patients: long-term survivors with >36 months overall survival (OS), short-term survivors with <12 months OS, and patients with intermediate OS.  Results provide insight into the molecular characterization of long-term survivors of glioblastoma.",24615357,GPL570,in situ oligonucleotide,54675,1,70,transformed count,GSE53733,none,data/GEO_v2/datasets/GDS5205.csv,958,disease state,3,"{'intermediate overall survival': 31, 'long-term overall survival': 23, 'short-term overall survival': 16}","{'intermediate overall survival': 0, 'long-term overall survival': 1, 'short-term overall survival': 0}",False
GDS4318,Single nucleotide polymorphism rs1333049 from the 9p21.3 coronary artery disease risk locus: normal heart,Analysis of left ventricular heart from donors with no previous history of heart disease. Results provide insight into associations between 9p21.3 (rs1333049) genotype and transcripts in cardiovascular tissue.,22768093,GPL6244,in situ oligonucleotide,33297,1,108,transformed count,GSE22253,none,data/GEO_v2/datasets/GDS4318.csv,959,genotype/variation,3,"{'rs1333049 genotype: GC': 55, 'rs1333049 genotype: GG': 32, 'rs1333049 genotype: CC': 21}","{'rs1333049 genotype: GC': 0, 'rs1333049 genotype: GG': 0, 'rs1333049 genotype: CC': 1}",False
GDS4318,Single nucleotide polymorphism rs1333049 from the 9p21.3 coronary artery disease risk locus: normal heart,Analysis of left ventricular heart from donors with no previous history of heart disease. Results provide insight into associations between 9p21.3 (rs1333049) genotype and transcripts in cardiovascular tissue.,22768093,GPL6244,in situ oligonucleotide,33297,1,108,transformed count,GSE22253,none,data/GEO_v2/datasets/GDS4318.csv,959,genotype/variation,3,"{'rs1333049 genotype: GC': 55, 'rs1333049 genotype: GG': 32, 'rs1333049 genotype: CC': 21}","{'rs1333049 genotype: GC': 0, 'rs1333049 genotype: GG': 1, 'rs1333049 genotype: CC': 0}",False
GDS4318,Single nucleotide polymorphism rs1333049 from the 9p21.3 coronary artery disease risk locus: normal heart,Analysis of left ventricular heart from donors with no previous history of heart disease. Results provide insight into associations between 9p21.3 (rs1333049) genotype and transcripts in cardiovascular tissue.,22768093,GPL6244,in situ oligonucleotide,33297,1,108,transformed count,GSE22253,none,data/GEO_v2/datasets/GDS4318.csv,959,genotype/variation,3,"{'rs1333049 genotype: GC': 55, 'rs1333049 genotype: GG': 32, 'rs1333049 genotype: CC': 21}","{'rs1333049 genotype: GC': 0, 'rs1333049 genotype: GG': 1, 'rs1333049 genotype: CC': 1}",False
GDS4267,Systemic juvenile idiopathic arthritis and non-systemic JIA subtypes: peripheral blood mononuclear cells,"Analysis of PBMCs from patients with systemic juvenile idiopathic arthritis (sJIA) or non-sJIA. sJIA patients have significantly increased expansion of  immature PBMC subpopulations,  including CD34+ cells. Results provide insight into molecular mechanisms underlying sJIA pathogenesis.",20576155,GPL570,in situ oligonucleotide,54675,1,154,transformed count,GSE21521,none,data/GEO_v2/datasets/GDS4267.csv,958,disease state,3,"{'non-systemic JIA': 107, 'healthy': 29, 'systemic JIA': 18}","{'non-systemic JIA': 0, 'healthy': 0, 'systemic JIA': 1}",False
GDS4267,Systemic juvenile idiopathic arthritis and non-systemic JIA subtypes: peripheral blood mononuclear cells,"Analysis of PBMCs from patients with systemic juvenile idiopathic arthritis (sJIA) or non-sJIA. sJIA patients have significantly increased expansion of  immature PBMC subpopulations,  including CD34+ cells. Results provide insight into molecular mechanisms underlying sJIA pathogenesis.",20576155,GPL570,in situ oligonucleotide,54675,1,154,transformed count,GSE21521,none,data/GEO_v2/datasets/GDS4267.csv,958,disease state,3,"{'non-systemic JIA': 107, 'healthy': 29, 'systemic JIA': 18}","{'non-systemic JIA': 0, 'healthy': 1, 'systemic JIA': 0}",False
GDS4267,Systemic juvenile idiopathic arthritis and non-systemic JIA subtypes: peripheral blood mononuclear cells,"Analysis of PBMCs from patients with systemic juvenile idiopathic arthritis (sJIA) or non-sJIA. sJIA patients have significantly increased expansion of  immature PBMC subpopulations,  including CD34+ cells. Results provide insight into molecular mechanisms underlying sJIA pathogenesis.",20576155,GPL570,in situ oligonucleotide,54675,1,154,transformed count,GSE21521,none,data/GEO_v2/datasets/GDS4267.csv,958,disease state,3,"{'non-systemic JIA': 107, 'healthy': 29, 'systemic JIA': 18}","{'non-systemic JIA': 0, 'healthy': 1, 'systemic JIA': 1}",False
GDS5363,Osteoarthritis: peripheral blood mononuclear cells,Analysis of peripheral blood mononuclear cells (PBMCs) from osteoarthritis (OA) patients. Patients participated in the Genetics osteoARthritis and Progression (GARP) study. Results provide insight into the feasibility of using gene expression profiling of PBMCs to detect the onset of OA.,23864235,GPL6947,oligonucleotide beads,49576,1,139,transformed count,GSE48556,none,data/GEO_v2/datasets/GDS5363.csv,965,disease state,2,"{'osteoarthritis': 106, 'control': 33}","{'osteoarthritis': 0, 'control': 1}",True
GDS5363,Osteoarthritis: peripheral blood mononuclear cells,Analysis of peripheral blood mononuclear cells (PBMCs) from osteoarthritis (OA) patients. Patients participated in the Genetics osteoARthritis and Progression (GARP) study. Results provide insight into the feasibility of using gene expression profiling of PBMCs to detect the onset of OA.,23864235,GPL6947,oligonucleotide beads,49576,1,139,transformed count,GSE48556,none,data/GEO_v2/datasets/GDS5363.csv,965,gender,2,"{'female': 129, 'male': 10}","{'female': 0, 'male': 1}",True
GDS4129,Endoplasmic reticulum stress effect on lymphoblastoid cells of unrelated individuals,Analysis of immortalized B cells from 60 unrelated individuals (grandparents in the HapMap CEPH-Utah pedigrees) treated in vitro with tunicamycin to induce ER stress.  ER stress induces the unfolded protein response (UPR). Results provide insight into molecular mechanisms underlying UPR response.,20398888,GPL570,in situ oligonucleotide,54675,1,120,transformed count,GSE19519,none,data/GEO_v2/datasets/GDS4129.csv,958,agent,2,"{'tunicamycin': 60, 'control': 60}","{'tunicamycin': 0, 'control': 1}",False
GDS4600,Psoriasis vulgaris ACCEPT cohort: paired lesional and non-lesional skin,Analysis of 85 paired lesional and non-lesional samples from moderate-to-severe psoriasis patients at baseline without active psoriasis therapy. Results provide insight into the molecular mechanisms underlying psoriasis.,22763790,GPL570,in situ oligonucleotide,54675,1,170,transformed count,GSE30999,none,data/GEO_v2/datasets/GDS4600.csv,958,disease state,2,"{'non-lesion': 85, 'psoriasis lesion': 85}","{'non-lesion': 0, 'psoriasis lesion': 1}",True
GDS4181,WHO 2008-classified acute myeloid leukemia subgroups (Analysis I): bone marrow mononuclear cells,Analysis of BMMCs from untreated patients diagnosed as AML-MLD-sole (AML with myelodysplasia-related changes solely because of multilineage dysplasia) or AML-NOS (AML-not otherwise specified) according to WHO 2008 guidelines. Results provide insight into the relevance of MLD for AML classification.,20581309,GPL570,in situ oligonucleotide,54675,1,80,transformed count,GSE21261,none,data/GEO_v2/datasets/GDS4181.csv,958,disease state,2,"{'AML-not otherwise specified (AML-NOS)': 56, 'AML-multilineage dysplasia sole (AML-MLD-sole)': 24}","{'AML-not otherwise specified (AML-NOS)': 0, 'AML-multilineage dysplasia sole (AML-MLD-sole)': 1}",False
GDS4336,Pancreatic ductal adenocarcinoma tumor and adjacent non-tumor tissue,Analysis of 45 matching pairs of pancreatic ductal adenocarcinoma (PDAC) tumor and adjacent non-tumor tissue. Results provide insight into tumor markers with prognostic significance and molecular mechanisms underlying PDAC.,"['22363658', '23918603']",GPL6244,in situ oligonucleotide,33297,1,90,transformed count,GSE28735,none,data/GEO_v2/datasets/GDS4336.csv,959,tissue,2,"{'PDAC tumor': 45, 'non-tumor tissue': 45}","{'PDAC tumor': 0, 'non-tumor tissue': 1}",False
GDS4336,Pancreatic ductal adenocarcinoma tumor and adjacent non-tumor tissue,Analysis of 45 matching pairs of pancreatic ductal adenocarcinoma (PDAC) tumor and adjacent non-tumor tissue. Results provide insight into tumor markers with prognostic significance and molecular mechanisms underlying PDAC.,"['22363658', '23918603']",GPL6244,in situ oligonucleotide,33297,1,90,transformed count,GSE28735,none,data/GEO_v2/datasets/GDS4336.csv,959,disease state,3,"{'cancer death: 1': 58, 'cancer death: 0': 26, 'cancer death: na': 6}","{'cancer death: 1': 0, 'cancer death: 0': 1, 'cancer death: na': 1}",False
GDS5277,Rheumatoid arthritis and response to anti-TNF therapy: blood,Analysis of blood from rheumatoid arthritis (RA) patients prior to anti-TNF therapy. Response of patients to anti-TNF therapy assessed after 14 weeks. Results identify a gene expression signature for predicting the response to anti-TNF therapy.,19699293,GPL570,in situ oligonucleotide,54675,1,86,transformed count,GSE15258,none,data/GEO_v2/datasets/GDS5277.csv,958,other,4,"{'moderate responder': 29, 'responder': 24, 'non-responder': 22, 'unknown': 11}","{'moderate responder': 1, 'responder': 0, 'non-responder': 0, 'unknown': 0}",False
GDS5277,Rheumatoid arthritis and response to anti-TNF therapy: blood,Analysis of blood from rheumatoid arthritis (RA) patients prior to anti-TNF therapy. Response of patients to anti-TNF therapy assessed after 14 weeks. Results identify a gene expression signature for predicting the response to anti-TNF therapy.,19699293,GPL570,in situ oligonucleotide,54675,1,86,transformed count,GSE15258,none,data/GEO_v2/datasets/GDS5277.csv,958,other,4,"{'moderate responder': 29, 'responder': 24, 'non-responder': 22, 'unknown': 11}","{'moderate responder': 0, 'responder': 0, 'non-responder': 1, 'unknown': 1}",False
GDS5277,Rheumatoid arthritis and response to anti-TNF therapy: blood,Analysis of blood from rheumatoid arthritis (RA) patients prior to anti-TNF therapy. Response of patients to anti-TNF therapy assessed after 14 weeks. Results identify a gene expression signature for predicting the response to anti-TNF therapy.,19699293,GPL570,in situ oligonucleotide,54675,1,86,transformed count,GSE15258,none,data/GEO_v2/datasets/GDS5277.csv,958,other,4,"{'moderate responder': 29, 'responder': 24, 'non-responder': 22, 'unknown': 11}","{'moderate responder': 0, 'responder': 1, 'non-responder': 0, 'unknown': 0}",False
GDS2771,Large airway epithelial cells from cigarette smokers with suspect lung cancer,"Analysis of large airway epithelial cells from cigarette smokers without cancer, with cancer, and with suspect lung cancer. Results provide insight into the feasibility of using gene expression to detect early stage lung cancer in smokers.","['17334370', '20375364']",GPL96,in situ oligonucleotide,22283,1,192,transformed count,GSE4115,none,data/GEO_v2/datasets/GDS2771.csv,958,disease state,3,"{'cancer': 97, 'no cancer': 90, 'suspect cancer': 5}","{'cancer': 0, 'no cancer': 1, 'suspect cancer': 0}",False
GDS4607,Psoriasis non-lesional skin response to interferon-γ,Analysis of non-lesional (NL) skin of psoriasis patients 24 hrs after a single intradermal injection of interferon-γ (IFN-γ) to the NL skin. Results suggest that IFN-γ may prime an inflammatory environment in the skin that shares many features with psoriasis.,22277938,GPL571,in situ oligonucleotide,22277,1,60,transformed count,GSE32407,none,data/GEO_v2/datasets/GDS4607.csv,958,disease state,2,"{'psoriasis': 30, 'healthy': 30}","{'psoriasis': 0, 'healthy': 1}",True
GDS4607,Psoriasis non-lesional skin response to interferon-γ,Analysis of non-lesional (NL) skin of psoriasis patients 24 hrs after a single intradermal injection of interferon-γ (IFN-γ) to the NL skin. Results suggest that IFN-γ may prime an inflammatory environment in the skin that shares many features with psoriasis.,22277938,GPL571,in situ oligonucleotide,22277,1,60,transformed count,GSE32407,none,data/GEO_v2/datasets/GDS4607.csv,958,protocol,3,"{'baseline': 20, 'interferon-Î³ injection': 20, 'placebo': 20}","{'baseline': 0, 'interferon-Î³ injection': 1, 'placebo': 0}",True
GDS4176,"Chronic lymphocytic leukemia: peripheral blood, bone marrow and lymph node matched samples","Analysis of purified CLL cells from 24 treatment-naive patients. Samples were obtained concurrently from peripheral blood (PB), bone marrow (BM) and/or lymph nodes (LN). Results provide insight into the role of the tissue microenvironment in the pathogenesis of CLL in vivo.",20940416,GPL570,in situ oligonucleotide,54675,1,62,transformed count,GSE21029,none,data/GEO_v2/datasets/GDS4176.csv,958,tissue,3,"{'peripheral blood': 26, 'bone marrow': 19, 'lymph node': 17}","{'peripheral blood': 0, 'bone marrow': 0, 'lymph node': 1}",True
GDS4176,"Chronic lymphocytic leukemia: peripheral blood, bone marrow and lymph node matched samples","Analysis of purified CLL cells from 24 treatment-naive patients. Samples were obtained concurrently from peripheral blood (PB), bone marrow (BM) and/or lymph nodes (LN). Results provide insight into the role of the tissue microenvironment in the pathogenesis of CLL in vivo.",20940416,GPL570,in situ oligonucleotide,54675,1,62,transformed count,GSE21029,none,data/GEO_v2/datasets/GDS4176.csv,958,tissue,3,"{'peripheral blood': 26, 'bone marrow': 19, 'lymph node': 17}","{'peripheral blood': 0, 'bone marrow': 1, 'lymph node': 0}",True
GDS4176,"Chronic lymphocytic leukemia: peripheral blood, bone marrow and lymph node matched samples","Analysis of purified CLL cells from 24 treatment-naive patients. Samples were obtained concurrently from peripheral blood (PB), bone marrow (BM) and/or lymph nodes (LN). Results provide insight into the role of the tissue microenvironment in the pathogenesis of CLL in vivo.",20940416,GPL570,in situ oligonucleotide,54675,1,62,transformed count,GSE21029,none,data/GEO_v2/datasets/GDS4176.csv,958,tissue,3,"{'peripheral blood': 26, 'bone marrow': 19, 'lymph node': 17}","{'peripheral blood': 1, 'bone marrow': 0, 'lymph node': 0}",True
GDS4562,Squamous cell carcinoma of the tongue: tumors and histologically normal surgical margins,"Analysis of oral carcinoma, histologically normal margins, and adjacent normal tissues from patients with squamous cell carcinoma (OSCC) of the tongue (training set). Results provide insight into molecular signature in histologically normal margins that is predictive of oral carcinoma recurrence.",21989116,GPL10526,in situ oligonucleotide,17788,1,96,transformed count,GSE31056,none,data/GEO_v2/datasets/GDS4562.csv,963,specimen,2,"{'margin': 73, 'tumor': 23}","{'margin': 0, 'tumor': 1}",True
GDS4562,Squamous cell carcinoma of the tongue: tumors and histologically normal surgical margins,"Analysis of oral carcinoma, histologically normal margins, and adjacent normal tissues from patients with squamous cell carcinoma (OSCC) of the tongue (training set). Results provide insight into molecular signature in histologically normal margins that is predictive of oral carcinoma recurrence.",21989116,GPL10526,in situ oligonucleotide,17788,1,96,transformed count,GSE31056,none,data/GEO_v2/datasets/GDS4562.csv,963,disease state,2,"{'no recurrence': 58, 'disease recurrence': 38}","{'no recurrence': 0, 'disease recurrence': 1}",True
GDS4103,ICF cohort: Whole-tissue pancreatic ductal adenocarcinoma,"Analysis of pancreatic ductal adenocarcinoma (PDAC) tumors and matching normal pancreatic tissue from ICF pancreatic cancer patients. PDAC is an aggressive, rapidly disseminating, desmoplastic cancer with poor prognosis. Results provide insight into molecular processes involved in PDAC pathology.",19260470,GPL570,in situ oligonucleotide,54675,1,78,transformed count,GSE15471,none,data/GEO_v2/datasets/GDS4103.csv,958,tissue,2,"{'PDAC tumor': 39, 'normal pancreatic': 39}","{'PDAC tumor': 0, 'normal pancreatic': 1}",False
GDS5393,Bipolar disorder and response to lithium: blood,Analysis of peripheral blood from patients with bipolar disorder before and 1 month after lithium treatment. Response of patients to lithium assessed after 6 months. Results identify a gene expression signature for the response to lithium treatment in patients with bipolar disorder.,23670706,GPL10558,oligonucleotide beads,48107,1,120,transformed count,GSE45484,none,data/GEO_v2/datasets/GDS5393.csv,965,agent,2,"{'control': 64, 'lithium': 56}","{'control': 0, 'lithium': 1}",True
GDS5393,Bipolar disorder and response to lithium: blood,Analysis of peripheral blood from patients with bipolar disorder before and 1 month after lithium treatment. Response of patients to lithium assessed after 6 months. Results identify a gene expression signature for the response to lithium treatment in patients with bipolar disorder.,23670706,GPL10558,oligonucleotide beads,48107,1,120,transformed count,GSE45484,none,data/GEO_v2/datasets/GDS5393.csv,965,other,2,"{'non-responder': 94, 'responder': 26}","{'non-responder': 0, 'responder': 1}",True
GDS5393,Bipolar disorder and response to lithium: blood,Analysis of peripheral blood from patients with bipolar disorder before and 1 month after lithium treatment. Response of patients to lithium assessed after 6 months. Results identify a gene expression signature for the response to lithium treatment in patients with bipolar disorder.,23670706,GPL10558,oligonucleotide beads,48107,1,120,transformed count,GSE45484,none,data/GEO_v2/datasets/GDS5393.csv,965,time,2,"{'baseline': 60, '1 month': 60}","{'baseline': 0, '1 month': 1}",True
GDS4198,Australian patient cohort: gastric adenocarcinoma,"Analysis of 70 primary gastric tumors representing 3 subtypes (invasive, metabolic, and proliferative) from the Australian patient cohort (AU-2). Gastric adenocarcinomas show sizable heterogeneity between patients. Results provide insight into molecular characterization of gastric cancer subtypes.","['22735568', '25053715', '23684942']",GPL570,in situ oligonucleotide,54675,1,70,transformed count,GSE35809,none,data/GEO_v2/datasets/GDS4198.csv,958,disease state,3,"{'gastric cancer subtype: proliferative': 29, 'gastric cancer subtype: invasive': 26, 'gastric cancer subtype: metabolic': 15}","{'gastric cancer subtype: proliferative': 0, 'gastric cancer subtype: invasive': 0, 'gastric cancer subtype: metabolic': 1}",False
GDS4198,Australian patient cohort: gastric adenocarcinoma,"Analysis of 70 primary gastric tumors representing 3 subtypes (invasive, metabolic, and proliferative) from the Australian patient cohort (AU-2). Gastric adenocarcinomas show sizable heterogeneity between patients. Results provide insight into molecular characterization of gastric cancer subtypes.","['22735568', '25053715', '23684942']",GPL570,in situ oligonucleotide,54675,1,70,transformed count,GSE35809,none,data/GEO_v2/datasets/GDS4198.csv,958,disease state,3,"{'gastric cancer subtype: proliferative': 29, 'gastric cancer subtype: invasive': 26, 'gastric cancer subtype: metabolic': 15}","{'gastric cancer subtype: proliferative': 0, 'gastric cancer subtype: invasive': 1, 'gastric cancer subtype: metabolic': 0}",False
GDS4198,Australian patient cohort: gastric adenocarcinoma,"Analysis of 70 primary gastric tumors representing 3 subtypes (invasive, metabolic, and proliferative) from the Australian patient cohort (AU-2). Gastric adenocarcinomas show sizable heterogeneity between patients. Results provide insight into molecular characterization of gastric cancer subtypes.","['22735568', '25053715', '23684942']",GPL570,in situ oligonucleotide,54675,1,70,transformed count,GSE35809,none,data/GEO_v2/datasets/GDS4198.csv,958,disease state,3,"{'gastric cancer subtype: proliferative': 29, 'gastric cancer subtype: invasive': 26, 'gastric cancer subtype: metabolic': 15}","{'gastric cancer subtype: proliferative': 1, 'gastric cancer subtype: invasive': 0, 'gastric cancer subtype: metabolic': 0}",False
GDS4379,Colorectal cancer tumors,Analysis of primary colorectal cancer (CRC) tumors. CRC is a heterogeneous disease. Results provide insight into stratifying CRC tumor samples into subtypes and tailoring treatments for the CRC subtypes.,23272949,GPL570,in situ oligonucleotide,54675,1,62,transformed count,GSE35896,none,data/GEO_v2/datasets/GDS4379.csv,958,disease state,6,"{'Large Intestine, Adenocarcinoma': 55, 'Adenocarcinoma': 2, 'Large Intestine, Mucinous Adenocarcinoma': 2, 'Large Intestine, Adenocarcinoma in Villous Adenoma': 1, 'Large Intestine, Villous Adenoma': 1, 'Mucinous Adenocarcinoma': 1}","{'Large Intestine, Adenocarcinoma': 0, 'Adenocarcinoma': 0, 'Large Intestine, Mucinous Adenocarcinoma': 1, 'Large Intestine, Adenocarcinoma in Villous Adenoma': 0, 'Large Intestine, Villous Adenoma': 1, 'Mucinous Adenocarcinoma': 1}",False
GDS4379,Colorectal cancer tumors,Analysis of primary colorectal cancer (CRC) tumors. CRC is a heterogeneous disease. Results provide insight into stratifying CRC tumor samples into subtypes and tailoring treatments for the CRC subtypes.,23272949,GPL570,in situ oligonucleotide,54675,1,62,transformed count,GSE35896,none,data/GEO_v2/datasets/GDS4379.csv,958,disease state,6,"{'Large Intestine, Adenocarcinoma': 55, 'Adenocarcinoma': 2, 'Large Intestine, Mucinous Adenocarcinoma': 2, 'Large Intestine, Adenocarcinoma in Villous Adenoma': 1, 'Large Intestine, Villous Adenoma': 1, 'Mucinous Adenocarcinoma': 1}","{'Large Intestine, Adenocarcinoma': 0, 'Adenocarcinoma': 0, 'Large Intestine, Mucinous Adenocarcinoma': 1, 'Large Intestine, Adenocarcinoma in Villous Adenoma': 0, 'Large Intestine, Villous Adenoma': 0, 'Mucinous Adenocarcinoma': 1}",False
GDS4379,Colorectal cancer tumors,Analysis of primary colorectal cancer (CRC) tumors. CRC is a heterogeneous disease. Results provide insight into stratifying CRC tumor samples into subtypes and tailoring treatments for the CRC subtypes.,23272949,GPL570,in situ oligonucleotide,54675,1,62,transformed count,GSE35896,none,data/GEO_v2/datasets/GDS4379.csv,958,disease state,6,"{'Large Intestine, Adenocarcinoma': 55, 'Adenocarcinoma': 2, 'Large Intestine, Mucinous Adenocarcinoma': 2, 'Large Intestine, Adenocarcinoma in Villous Adenoma': 1, 'Large Intestine, Villous Adenoma': 1, 'Mucinous Adenocarcinoma': 1}","{'Large Intestine, Adenocarcinoma': 0, 'Adenocarcinoma': 0, 'Large Intestine, Mucinous Adenocarcinoma': 0, 'Large Intestine, Adenocarcinoma in Villous Adenoma': 1, 'Large Intestine, Villous Adenoma': 1, 'Mucinous Adenocarcinoma': 0}",False
GDS4379,Colorectal cancer tumors,Analysis of primary colorectal cancer (CRC) tumors. CRC is a heterogeneous disease. Results provide insight into stratifying CRC tumor samples into subtypes and tailoring treatments for the CRC subtypes.,23272949,GPL570,in situ oligonucleotide,54675,1,62,transformed count,GSE35896,none,data/GEO_v2/datasets/GDS4379.csv,958,disease state,6,"{'Large Intestine, Adenocarcinoma': 55, 'Adenocarcinoma': 2, 'Large Intestine, Mucinous Adenocarcinoma': 2, 'Large Intestine, Adenocarcinoma in Villous Adenoma': 1, 'Large Intestine, Villous Adenoma': 1, 'Mucinous Adenocarcinoma': 1}","{'Large Intestine, Adenocarcinoma': 0, 'Adenocarcinoma': 1, 'Large Intestine, Mucinous Adenocarcinoma': 0, 'Large Intestine, Adenocarcinoma in Villous Adenoma': 0, 'Large Intestine, Villous Adenoma': 0, 'Mucinous Adenocarcinoma': 1}",False
GDS4379,Colorectal cancer tumors,Analysis of primary colorectal cancer (CRC) tumors. CRC is a heterogeneous disease. Results provide insight into stratifying CRC tumor samples into subtypes and tailoring treatments for the CRC subtypes.,23272949,GPL570,in situ oligonucleotide,54675,1,62,transformed count,GSE35896,none,data/GEO_v2/datasets/GDS4379.csv,958,genotype/variation,3,"{'microsatellite.status: MSS': 56, 'microsatellite.status: MSI': 5, 'microsatellite.status: ---': 1}","{'microsatellite.status: MSS': 0, 'microsatellite.status: MSI': 1, 'microsatellite.status: ---': 1}",False
GDS4968,Monoclonal gammopathies: bone marrow plasma cells,"Analysis of plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (MM), or MM. MM is consistently preceded by MGUS/SMM. Results provide insight into molecular mechanisms underlying the transformation from precursor disease to MM.",24816239,GPL6244,in situ oligonucleotide,33297,1,99,transformed count,GSE47552,none,data/GEO_v2/datasets/GDS4968.csv,959,disease state,4,"{'multiple myeloma': 41, 'smoldering multiple myeloma': 33, 'monoclonal gammopathy of undetermined significance': 20, 'normal': 5}","{'multiple myeloma': 0, 'smoldering multiple myeloma': 0, 'monoclonal gammopathy of undetermined significance': 1, 'normal': 1}",True
GDS4412,Dietary fatty acid composition effect on vastus lateralis muscle,"Analysis of skeletal muscle (SM) from insulin resistant men 4 hrs after consumption of meals high in saturated FA (SFA), monounsaturated FA (MUFA), or polyunsaturated FA (PUFA). Results provide insight into mechanisms underlying effects of FA composition on SM FA handling and insulin sensitivity.",22338035,GPL6244,in situ oligonucleotide,33297,1,56,transformed count,GSE31901,none,data/GEO_v2/datasets/GDS4412.csv,959,protocol,3,"{'monounsaturated FA': 20, 'saturated FA': 18, 'polyunsaturated FA': 18}","{'monounsaturated FA': 0, 'saturated FA': 0, 'polyunsaturated FA': 1}",False
GDS4412,Dietary fatty acid composition effect on vastus lateralis muscle,"Analysis of skeletal muscle (SM) from insulin resistant men 4 hrs after consumption of meals high in saturated FA (SFA), monounsaturated FA (MUFA), or polyunsaturated FA (PUFA). Results provide insight into mechanisms underlying effects of FA composition on SM FA handling and insulin sensitivity.",22338035,GPL6244,in situ oligonucleotide,33297,1,56,transformed count,GSE31901,none,data/GEO_v2/datasets/GDS4412.csv,959,protocol,3,"{'monounsaturated FA': 20, 'saturated FA': 18, 'polyunsaturated FA': 18}","{'monounsaturated FA': 0, 'saturated FA': 1, 'polyunsaturated FA': 0}",False
GDS4412,Dietary fatty acid composition effect on vastus lateralis muscle,"Analysis of skeletal muscle (SM) from insulin resistant men 4 hrs after consumption of meals high in saturated FA (SFA), monounsaturated FA (MUFA), or polyunsaturated FA (PUFA). Results provide insight into mechanisms underlying effects of FA composition on SM FA handling and insulin sensitivity.",22338035,GPL6244,in situ oligonucleotide,33297,1,56,transformed count,GSE31901,none,data/GEO_v2/datasets/GDS4412.csv,959,protocol,3,"{'monounsaturated FA': 20, 'saturated FA': 18, 'polyunsaturated FA': 18}","{'monounsaturated FA': 1, 'saturated FA': 0, 'polyunsaturated FA': 0}",False
GDS4056,ER-positive/HER2-negative and ER-negative/HER2-negative breast cancer biopsies (USO-02103 cohort),Analysis of pre-treatment biopsies from 62 HER2-normal breast cancer patients (ER-positive and ER-negative subtypes) from US Oncology clinical trial 02103. Results provide insight into molecular mechanisms associated with chemotherapy sensitivity in breast cancer subtypes.,21191116,GPL96,in situ oligonucleotide,22283,1,61,transformed count,GSE23988,none,data/GEO_v2/datasets/GDS4056.csv,958,disease state,3,"{'prechemo T stage 3': 40, 'prechemo T stage 2': 20, 'prechemo T stage 1': 1}","{'prechemo T stage 3': 0, 'prechemo T stage 2': 0, 'prechemo T stage 1': 1}",False
GDS4056,ER-positive/HER2-negative and ER-negative/HER2-negative breast cancer biopsies (USO-02103 cohort),Analysis of pre-treatment biopsies from 62 HER2-normal breast cancer patients (ER-positive and ER-negative subtypes) from US Oncology clinical trial 02103. Results provide insight into molecular mechanisms associated with chemotherapy sensitivity in breast cancer subtypes.,21191116,GPL96,in situ oligonucleotide,22283,1,61,transformed count,GSE23988,none,data/GEO_v2/datasets/GDS4056.csv,958,disease state,3,"{'prechemo T stage 3': 40, 'prechemo T stage 2': 20, 'prechemo T stage 1': 1}","{'prechemo T stage 3': 0, 'prechemo T stage 2': 1, 'prechemo T stage 1': 0}",False
GDS4056,ER-positive/HER2-negative and ER-negative/HER2-negative breast cancer biopsies (USO-02103 cohort),Analysis of pre-treatment biopsies from 62 HER2-normal breast cancer patients (ER-positive and ER-negative subtypes) from US Oncology clinical trial 02103. Results provide insight into molecular mechanisms associated with chemotherapy sensitivity in breast cancer subtypes.,21191116,GPL96,in situ oligonucleotide,22283,1,61,transformed count,GSE23988,none,data/GEO_v2/datasets/GDS4056.csv,958,disease state,3,"{'prechemo T stage 3': 40, 'prechemo T stage 2': 20, 'prechemo T stage 1': 1}","{'prechemo T stage 3': 0, 'prechemo T stage 2': 1, 'prechemo T stage 1': 1}",False
GDS4056,ER-positive/HER2-negative and ER-negative/HER2-negative breast cancer biopsies (USO-02103 cohort),Analysis of pre-treatment biopsies from 62 HER2-normal breast cancer patients (ER-positive and ER-negative subtypes) from US Oncology clinical trial 02103. Results provide insight into molecular mechanisms associated with chemotherapy sensitivity in breast cancer subtypes.,21191116,GPL96,in situ oligonucleotide,22283,1,61,transformed count,GSE23988,none,data/GEO_v2/datasets/GDS4056.csv,958,genotype/variation,2,"{'ER +': 32, 'ER -': 29}","{'ER +': 0, 'ER -': 1}",False
GDS4056,ER-positive/HER2-negative and ER-negative/HER2-negative breast cancer biopsies (USO-02103 cohort),Analysis of pre-treatment biopsies from 62 HER2-normal breast cancer patients (ER-positive and ER-negative subtypes) from US Oncology clinical trial 02103. Results provide insight into molecular mechanisms associated with chemotherapy sensitivity in breast cancer subtypes.,21191116,GPL96,in situ oligonucleotide,22283,1,61,transformed count,GSE23988,none,data/GEO_v2/datasets/GDS4056.csv,958,other,2,"{'postchemo: residual invasive cancer': 41, 'postchemo: no invasive cancer': 20}","{'postchemo: residual invasive cancer': 0, 'postchemo: no invasive cancer': 1}",False
GDS3539,Psoriasis,"Analysis of lesional and non-lesional skins from patients with psoriasis. Psoriasis is an immune-mediated disease characterized by aberrant epidermal differentiation, surface scale formation, and marked cutaneous inflammation. Results provide insight into the molecular pathogenesis of psoriasis.",18648529,GPL570,in situ oligonucleotide,54675,1,82,transformed count,GSE14905,none,data/GEO_v2/datasets/GDS3539.csv,958,disease state,2,"{'psoriasis': 61, 'control': 21}","{'psoriasis': 0, 'control': 1}",False
GDS3539,Psoriasis,"Analysis of lesional and non-lesional skins from patients with psoriasis. Psoriasis is an immune-mediated disease characterized by aberrant epidermal differentiation, surface scale formation, and marked cutaneous inflammation. Results provide insight into the molecular pathogenesis of psoriasis.",18648529,GPL570,in situ oligonucleotide,54675,1,82,transformed count,GSE14905,none,data/GEO_v2/datasets/GDS3539.csv,958,specimen,3,"{'lesional': 33, 'non-lesional': 28, 'normal': 21}","{'lesional': 0, 'non-lesional': 0, 'normal': 1}",False
GDS3539,Psoriasis,"Analysis of lesional and non-lesional skins from patients with psoriasis. Psoriasis is an immune-mediated disease characterized by aberrant epidermal differentiation, surface scale formation, and marked cutaneous inflammation. Results provide insight into the molecular pathogenesis of psoriasis.",18648529,GPL570,in situ oligonucleotide,54675,1,82,transformed count,GSE14905,none,data/GEO_v2/datasets/GDS3539.csv,958,specimen,3,"{'lesional': 33, 'non-lesional': 28, 'normal': 21}","{'lesional': 0, 'non-lesional': 1, 'normal': 0}",False
GDS3539,Psoriasis,"Analysis of lesional and non-lesional skins from patients with psoriasis. Psoriasis is an immune-mediated disease characterized by aberrant epidermal differentiation, surface scale formation, and marked cutaneous inflammation. Results provide insight into the molecular pathogenesis of psoriasis.",18648529,GPL570,in situ oligonucleotide,54675,1,82,transformed count,GSE14905,none,data/GEO_v2/datasets/GDS3539.csv,958,specimen,3,"{'lesional': 33, 'non-lesional': 28, 'normal': 21}","{'lesional': 1, 'non-lesional': 0, 'normal': 0}",False
GDS4516,Colorectal cancer: laser microdissected tumor tissues,Analysis of LCM-isolated colorectal cancer (CRC) tumors representing various stages and metastases. Results provide insight into predictive biomarkers of metastasis and treatment targets in CRC.,21270110,GPL570,in situ oligonucleotide,54675,1,104,transformed count,GSE21510,none,data/GEO_v2/datasets/GDS4516.csv,958,disease state,3,"{'no metastasis': 66, 'metastasis': 20, 'metastatic recurrence': 18}","{'no metastasis': 0, 'metastasis': 1, 'metastatic recurrence': 1}",True
GDS4516,Colorectal cancer: laser microdissected tumor tissues,Analysis of LCM-isolated colorectal cancer (CRC) tumors representing various stages and metastases. Results provide insight into predictive biomarkers of metastasis and treatment targets in CRC.,21270110,GPL570,in situ oligonucleotide,54675,1,104,transformed count,GSE21510,none,data/GEO_v2/datasets/GDS4516.csv,958,other,7,"{'stage: 3b': 24, 'stage: 2a': 20, 'stage: 4': 20, 'stage: 2b': 17, 'stage: 1': 13, 'stage: 3c': 6, 'stage: 3a': 4}","{'stage: 3b': 0, 'stage: 2a': 0, 'stage: 4': 0, 'stage: 2b': 0, 'stage: 1': 1, 'stage: 3c': 0, 'stage: 3a': 0}",True
GDS4516,Colorectal cancer: laser microdissected tumor tissues,Analysis of LCM-isolated colorectal cancer (CRC) tumors representing various stages and metastases. Results provide insight into predictive biomarkers of metastasis and treatment targets in CRC.,21270110,GPL570,in situ oligonucleotide,54675,1,104,transformed count,GSE21510,none,data/GEO_v2/datasets/GDS4516.csv,958,other,7,"{'stage: 3b': 24, 'stage: 2a': 20, 'stage: 4': 20, 'stage: 2b': 17, 'stage: 1': 13, 'stage: 3c': 6, 'stage: 3a': 4}","{'stage: 3b': 0, 'stage: 2a': 1, 'stage: 4': 0, 'stage: 2b': 1, 'stage: 1': 0, 'stage: 3c': 0, 'stage: 3a': 0}",True
GDS4516,Colorectal cancer: laser microdissected tumor tissues,Analysis of LCM-isolated colorectal cancer (CRC) tumors representing various stages and metastases. Results provide insight into predictive biomarkers of metastasis and treatment targets in CRC.,21270110,GPL570,in situ oligonucleotide,54675,1,104,transformed count,GSE21510,none,data/GEO_v2/datasets/GDS4516.csv,958,other,7,"{'stage: 3b': 24, 'stage: 2a': 20, 'stage: 4': 20, 'stage: 2b': 17, 'stage: 1': 13, 'stage: 3c': 6, 'stage: 3a': 4}","{'stage: 3b': 1, 'stage: 2a': 0, 'stage: 4': 0, 'stage: 2b': 0, 'stage: 1': 0, 'stage: 3c': 1, 'stage: 3a': 1}",True
GDS4516,Colorectal cancer: laser microdissected tumor tissues,Analysis of LCM-isolated colorectal cancer (CRC) tumors representing various stages and metastases. Results provide insight into predictive biomarkers of metastasis and treatment targets in CRC.,21270110,GPL570,in situ oligonucleotide,54675,1,104,transformed count,GSE21510,none,data/GEO_v2/datasets/GDS4516.csv,958,other,7,"{'stage: 3b': 24, 'stage: 2a': 20, 'stage: 4': 20, 'stage: 2b': 17, 'stage: 1': 13, 'stage: 3c': 6, 'stage: 3a': 4}","{'stage: 3b': 0, 'stage: 2a': 0, 'stage: 4': 1, 'stage: 2b': 0, 'stage: 1': 0, 'stage: 3c': 0, 'stage: 3a': 0}",True
GDS4381,Patient-derived colorectal cancer explants,"Analysis of patient-derived colorectal cancer explants (PDCCE), generated by direct transplantation of human colorectal cancer (CRC) tissues into NOD-SCID mice, and matched patient CRC primary tumors. Results provide insight into the degree to which PDCCEs represent their primary human counterparts.",22675560,GPL570,in situ oligonucleotide,54675,1,64,transformed count,GSE35144,none,data/GEO_v2/datasets/GDS4381.csv,958,tissue,2,"{'PDCCE tumor': 37, 'human tumor': 27}","{'PDCCE tumor': 0, 'human tumor': 1}",False
GDS4167,Chronic lymphocytic leukemia: peripheral blood B cells (HG-U133A),"Analysis of peripheral blood B cells isolated from 41 untreated chronic lymphocytic leukemia (CLL) patients and 11 age-matched control subjects. B-cell CLL is the most common type of leukemia, mainly affecting adults. Results provide insight into molecular mechanisms underlying CLL pathogenesis.",20595513,GPL96,in situ oligonucleotide,22283,1,52,transformed count,GSE22529,none,data/GEO_v2/datasets/GDS4167.csv,958,disease state,2,"{'Chronic lymphocytic leukemia': 41, 'normal control': 11}","{'Chronic lymphocytic leukemia': 0, 'normal control': 1}",False
GDS3329,Cytogenetically normal acute myeloid leukemia_test set,Analysis of mononuclear cells from bone marrow or peripheral blood from a test set of adult patients with cytogenetically normal acute myeloid leukemia (CN-AML). CN-AML patients show heterogeneous treatment outcomes. Results provide insight into the prognostic value of a gene signature for CN-AML.,18716133,GPL570,in situ oligonucleotide,54675,1,79,transformed count,GSE12417,none,data/GEO_v2/datasets/GDS3329.csv,958,tissue,2,"{'bone marrow': 74, 'peripheral blood': 5}","{'bone marrow': 0, 'peripheral blood': 1}",True
GDS3627,Non-small lung cancer subtypes: adenocarcinoma and squamous cell carcinoma,Comparison of two non-small cell lung cancer histological subtypes: adenocarcinomas (AC) and squamous cell carcinomas (SCC). Results provide insight into the molecular differences between AC and SCC.,18486272,GPL570,in situ oligonucleotide,54675,1,58,transformed count,GSE10245,none,data/GEO_v2/datasets/GDS3627.csv,958,disease state,2,"{'adenocarcinoma': 40, 'squamous cell carcinoma': 18}","{'adenocarcinoma': 0, 'squamous cell carcinoma': 1}",True
GDS4222,Classic Hodgkins lymphoma diagnostic lymph-node biopsies,Analysis of diagnostic lymph-node biopsies from classic Hodgkins lymphoma HIV- patients before ABVD chemotherapy. Results identify gene expression signatures that correlate with treatment outcomes.,20220182,GPL570,in situ oligonucleotide,54675,1,130,transformed count,GSE17920,none,data/GEO_v2/datasets/GDS4222.csv,958,gender,2,"{'male': 73, 'female': 57}","{'male': 0, 'female': 1}",False
GDS4222,Classic Hodgkins lymphoma diagnostic lymph-node biopsies,Analysis of diagnostic lymph-node biopsies from classic Hodgkins lymphoma HIV- patients before ABVD chemotherapy. Results identify gene expression signatures that correlate with treatment outcomes.,20220182,GPL570,in situ oligonucleotide,54675,1,130,transformed count,GSE17920,none,data/GEO_v2/datasets/GDS4222.csv,958,disease state,4,"{'disease stage: 2': 67, 'disease stage: 3': 29, 'disease stage: 4': 18, 'disease stage: 1': 16}","{'disease stage: 2': 0, 'disease stage: 3': 0, 'disease stage: 4': 0, 'disease stage: 1': 1}",False
GDS4222,Classic Hodgkins lymphoma diagnostic lymph-node biopsies,Analysis of diagnostic lymph-node biopsies from classic Hodgkins lymphoma HIV- patients before ABVD chemotherapy. Results identify gene expression signatures that correlate with treatment outcomes.,20220182,GPL570,in situ oligonucleotide,54675,1,130,transformed count,GSE17920,none,data/GEO_v2/datasets/GDS4222.csv,958,disease state,4,"{'disease stage: 2': 67, 'disease stage: 3': 29, 'disease stage: 4': 18, 'disease stage: 1': 16}","{'disease stage: 2': 0, 'disease stage: 3': 0, 'disease stage: 4': 1, 'disease stage: 1': 0}",False
GDS4222,Classic Hodgkins lymphoma diagnostic lymph-node biopsies,Analysis of diagnostic lymph-node biopsies from classic Hodgkins lymphoma HIV- patients before ABVD chemotherapy. Results identify gene expression signatures that correlate with treatment outcomes.,20220182,GPL570,in situ oligonucleotide,54675,1,130,transformed count,GSE17920,none,data/GEO_v2/datasets/GDS4222.csv,958,disease state,4,"{'disease stage: 2': 67, 'disease stage: 3': 29, 'disease stage: 4': 18, 'disease stage: 1': 16}","{'disease stage: 2': 0, 'disease stage: 3': 1, 'disease stage: 4': 0, 'disease stage: 1': 0}",False
GDS4222,Classic Hodgkins lymphoma diagnostic lymph-node biopsies,Analysis of diagnostic lymph-node biopsies from classic Hodgkins lymphoma HIV- patients before ABVD chemotherapy. Results identify gene expression signatures that correlate with treatment outcomes.,20220182,GPL570,in situ oligonucleotide,54675,1,130,transformed count,GSE17920,none,data/GEO_v2/datasets/GDS4222.csv,958,disease state,4,"{'disease stage: 2': 67, 'disease stage: 3': 29, 'disease stage: 4': 18, 'disease stage: 1': 16}","{'disease stage: 2': 0, 'disease stage: 3': 1, 'disease stage: 4': 1, 'disease stage: 1': 1}",False
GDS4758,Postmortem Alzheimer's disease brains: Hisayama study,"Analysis of postmortem brain tissues (frontal cortex, temporal cortex, hippocampus) from male and female Hisayama residents pathologically diagnosed as having Alzheimer's disease (AD) or an AD-like disorder. Results provide insight into the molecular mechanisms underlying AD brain pathology.",23595620,GPL6244,in situ oligonucleotide,33297,1,79,transformed count,GSE36980,none,data/GEO_v2/datasets/GDS4758.csv,959,disease state,2,"{""non-Alzheimer's disease"": 47, ""Alzheimer's disease"": 32}","{""non-Alzheimer's disease"": 0, ""Alzheimer's disease"": 1}",False
GDS4758,Postmortem Alzheimer's disease brains: Hisayama study,"Analysis of postmortem brain tissues (frontal cortex, temporal cortex, hippocampus) from male and female Hisayama residents pathologically diagnosed as having Alzheimer's disease (AD) or an AD-like disorder. Results provide insight into the molecular mechanisms underlying AD brain pathology.",23595620,GPL6244,in situ oligonucleotide,33297,1,79,transformed count,GSE36980,none,data/GEO_v2/datasets/GDS4758.csv,959,tissue,3,"{'frontal cortex': 33, 'temporal cortex': 29, 'hippocampus': 17}","{'frontal cortex': 0, 'temporal cortex': 0, 'hippocampus': 1}",False
GDS4758,Postmortem Alzheimer's disease brains: Hisayama study,"Analysis of postmortem brain tissues (frontal cortex, temporal cortex, hippocampus) from male and female Hisayama residents pathologically diagnosed as having Alzheimer's disease (AD) or an AD-like disorder. Results provide insight into the molecular mechanisms underlying AD brain pathology.",23595620,GPL6244,in situ oligonucleotide,33297,1,79,transformed count,GSE36980,none,data/GEO_v2/datasets/GDS4758.csv,959,gender,2,"{'female': 42, 'male': 37}","{'female': 0, 'male': 1}",False
GDS3312,Cytogenetically normal acute myeloid leukemia_training set (HG-U133A),Analysis of mononuclear cells from bone marrow or peripheral blood from a training set of 163 adult patients with cytogenetically normal acute myeloid leukemia (CN-AML). Patients with CN-AML show heterogeneous treatment outcomes. Results provide insight into a prognostic gene signature for CN-AML.,18716133,GPL96,in situ oligonucleotide,22283,1,163,transformed count,GSE12417,none,data/GEO_v2/datasets/GDS3312.csv,958,tissue,2,"{'bone marrow': 161, 'peripheral blood': 2}","{'bone marrow': 0, 'peripheral blood': 1}",True
GDS4282,Clear-cell renal cell carcinoma tumors and tumorgrafts deficient for tumor suppressor BAP1 or PBRM1,"Analysis of BAP1- and PBRM1-deficient ccRCC primary tumors, tumors growing in immunodeficient mice (tumorgrafts), and matched normal kidney cortices. BAP1 loss, but not PBRM1 loss, is associated with high-grade tumors. Results provide insight into molecular classification of RCC subtypes.",22683710,GPL570,in situ oligonucleotide,54675,1,76,transformed count,GSE36895,none,data/GEO_v2/datasets/GDS4282.csv,958,tissue,11,"{'ccRCC tumor': 29, 'normal cortex': 23, 'tumorgraft _p0': 9, 'tumorgraft_p1': 3, 'tumorgraft_p2': 3, 'tumorgraft_p4': 3, 'tumorgraft_p8': 2, 'tumorgraft_p3': 1, 'tumorgraft_p7': 1, 'tumorgraft_p9': 1, 'tumorgraft_p1_from metastasis': 1}","{'ccRCC tumor': 1, 'normal cortex': 0, 'tumorgraft _p0': 0, 'tumorgraft_p1': 0, 'tumorgraft_p2': 0, 'tumorgraft_p4': 0, 'tumorgraft_p8': 0, 'tumorgraft_p3': 0, 'tumorgraft_p7': 0, 'tumorgraft_p9': 0, 'tumorgraft_p1_from metastasis': 0}",True
GDS4282,Clear-cell renal cell carcinoma tumors and tumorgrafts deficient for tumor suppressor BAP1 or PBRM1,"Analysis of BAP1- and PBRM1-deficient ccRCC primary tumors, tumors growing in immunodeficient mice (tumorgrafts), and matched normal kidney cortices. BAP1 loss, but not PBRM1 loss, is associated with high-grade tumors. Results provide insight into molecular classification of RCC subtypes.",22683710,GPL570,in situ oligonucleotide,54675,1,76,transformed count,GSE36895,none,data/GEO_v2/datasets/GDS4282.csv,958,tissue,11,"{'ccRCC tumor': 29, 'normal cortex': 23, 'tumorgraft _p0': 9, 'tumorgraft_p1': 3, 'tumorgraft_p2': 3, 'tumorgraft_p4': 3, 'tumorgraft_p8': 2, 'tumorgraft_p3': 1, 'tumorgraft_p7': 1, 'tumorgraft_p9': 1, 'tumorgraft_p1_from metastasis': 1}","{'ccRCC tumor': 0, 'normal cortex': 1, 'tumorgraft _p0': 0, 'tumorgraft_p1': 0, 'tumorgraft_p2': 0, 'tumorgraft_p4': 0, 'tumorgraft_p8': 0, 'tumorgraft_p3': 0, 'tumorgraft_p7': 0, 'tumorgraft_p9': 0, 'tumorgraft_p1_from metastasis': 0}",True
GDS4282,Clear-cell renal cell carcinoma tumors and tumorgrafts deficient for tumor suppressor BAP1 or PBRM1,"Analysis of BAP1- and PBRM1-deficient ccRCC primary tumors, tumors growing in immunodeficient mice (tumorgrafts), and matched normal kidney cortices. BAP1 loss, but not PBRM1 loss, is associated with high-grade tumors. Results provide insight into molecular classification of RCC subtypes.",22683710,GPL570,in situ oligonucleotide,54675,1,76,transformed count,GSE36895,none,data/GEO_v2/datasets/GDS4282.csv,958,tissue,11,"{'ccRCC tumor': 29, 'normal cortex': 23, 'tumorgraft _p0': 9, 'tumorgraft_p1': 3, 'tumorgraft_p2': 3, 'tumorgraft_p4': 3, 'tumorgraft_p8': 2, 'tumorgraft_p3': 1, 'tumorgraft_p7': 1, 'tumorgraft_p9': 1, 'tumorgraft_p1_from metastasis': 1}","{'ccRCC tumor': 0, 'normal cortex': 0, 'tumorgraft _p0': 1, 'tumorgraft_p1': 1, 'tumorgraft_p2': 1, 'tumorgraft_p4': 1, 'tumorgraft_p8': 1, 'tumorgraft_p3': 1, 'tumorgraft_p7': 1, 'tumorgraft_p9': 1, 'tumorgraft_p1_from metastasis': 1}",True
GDS4282,Clear-cell renal cell carcinoma tumors and tumorgrafts deficient for tumor suppressor BAP1 or PBRM1,"Analysis of BAP1- and PBRM1-deficient ccRCC primary tumors, tumors growing in immunodeficient mice (tumorgrafts), and matched normal kidney cortices. BAP1 loss, but not PBRM1 loss, is associated with high-grade tumors. Results provide insight into molecular classification of RCC subtypes.",22683710,GPL570,in situ oligonucleotide,54675,1,76,transformed count,GSE36895,none,data/GEO_v2/datasets/GDS4282.csv,958,genotype/variation,3,"{'BAP1 wild type/PBRM1 wild type': 45, 'BAP1 wild type/PBRM1 loss': 21, 'BAP1 loss/PBRM1 wild type': 10}","{'BAP1 wild type/PBRM1 wild type': 0, 'BAP1 wild type/PBRM1 loss': 0, 'BAP1 loss/PBRM1 wild type': 1}",True
GDS4282,Clear-cell renal cell carcinoma tumors and tumorgrafts deficient for tumor suppressor BAP1 or PBRM1,"Analysis of BAP1- and PBRM1-deficient ccRCC primary tumors, tumors growing in immunodeficient mice (tumorgrafts), and matched normal kidney cortices. BAP1 loss, but not PBRM1 loss, is associated with high-grade tumors. Results provide insight into molecular classification of RCC subtypes.",22683710,GPL570,in situ oligonucleotide,54675,1,76,transformed count,GSE36895,none,data/GEO_v2/datasets/GDS4282.csv,958,genotype/variation,3,"{'BAP1 wild type/PBRM1 wild type': 45, 'BAP1 wild type/PBRM1 loss': 21, 'BAP1 loss/PBRM1 wild type': 10}","{'BAP1 wild type/PBRM1 wild type': 0, 'BAP1 wild type/PBRM1 loss': 1, 'BAP1 loss/PBRM1 wild type': 0}",True
GDS4587,UCSF sarcoidosis and hypersensitivity pneumonitis cohort: peripheral blood mononuclear cells,Analysis of whole blood from sarcoidosis and hypersensitivity pneumonitis patients. Results provide insight into molecular mechanisms underlying sarcoidosis and hypersensitivity pneumonitis in peripheral blood.,"['21852540', '25142485']",GPL570,in situ oligonucleotide,54675,1,66,transformed count,GSE19314,none,data/GEO_v2/datasets/GDS4587.csv,958,disease state,5,"{'sarcoidosis': 38, 'healthy': 20, 'hypersensitivity pneumonitis': 6, 'sarcoidosis-associated hepatitis C virus infection': 1, 'bronchiolitis obliterans': 1}","{'sarcoidosis': 0, 'healthy': 1, 'hypersensitivity pneumonitis': 0, 'sarcoidosis-associated hepatitis C virus infection': 0, 'bronchiolitis obliterans': 0}",False
GDS4273,Pediatric age-specific host response to septic shock: whole blood,Analysis of whole blood from children (up to 10 years old) within 24hrs of PICU admission for septic shock. Sepsis therapies useful in adults and older children may have little effect in immunologically immature younger patients. Results provide insight into age-specific host response to sepsis.,21738952,GPL570,in situ oligonucleotide,54675,1,103,transformed count,GSE26378,none,data/GEO_v2/datasets/GDS4273.csv,958,disease state,2,"{'septic shock': 82, 'healthy control': 21}","{'septic shock': 0, 'healthy control': 1}",True
GDS4273,Pediatric age-specific host response to septic shock: whole blood,Analysis of whole blood from children (up to 10 years old) within 24hrs of PICU admission for septic shock. Sepsis therapies useful in adults and older children may have little effect in immunologically immature younger patients. Results provide insight into age-specific host response to sepsis.,21738952,GPL570,in situ oligonucleotide,54675,1,103,transformed count,GSE26378,none,data/GEO_v2/datasets/GDS4273.csv,958,other,2,"{'outcome: survivor': 91, 'outcome: nonsurvivor': 12}","{'outcome: survivor': 0, 'outcome: nonsurvivor': 1}",True
GDS5074,First-time acute myocardial infarction: peripheral blood,Analysis of circulating blood from first-time acute myocardial infarction (AMI) patients within 48 hours of MI. Results provide insight into molecular mechanisms underlying the response of circulating cells to first-time AMI.,24801707,GPL570,in situ oligonucleotide,54675,1,52,transformed count,GSE48060,none,data/GEO_v2/datasets/GDS5074.csv,958,disease state,2,"{'acute myocardial infarction': 31, 'normal control': 21}","{'acute myocardial infarction': 0, 'normal control': 1}",False
GDS4975,Follicular lymphoma and higher grade diffuse large B-cell lymphoma patients: lymph node tumor biopsies,Analysis of lymph node tumor from follicular lymphoma (FL) and higher grade diffuse large B-cell lymphoma (DLBCL) patients. Transformation of FL to a more aggressive disease is often followed by rapid progression and death. Results provide insight into the molecular basis of FL transformation.,24357726,GPL570,in situ oligonucleotide,54675,1,81,transformed count,GSE53820,none,data/GEO_v2/datasets/GDS4975.csv,958,disease state,5,"{'follicular lymphoma': 75, 'DLBCL': 2, 'DLBCL 50% and FL 50%': 2, 'DLBCL 30% and FL 70%': 1, 'DLBCL 10% and FL 90%': 1}","{'follicular lymphoma': 0, 'DLBCL': 1, 'DLBCL 50% and FL 50%': 1, 'DLBCL 30% and FL 70%': 1, 'DLBCL 10% and FL 90%': 1}",False
GDS3829,"Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy effect on chronic lymphocytic leukemia","Analysis of CD19+ selected B cells from CLL patients before and after chemoimmunotherapy regimens of rituximab (R), fludarabine and cyclophosphamide (FC), or RFC. Results provide insight into the molecular mechanisms underlying the beneficial effects of the chemoimmunotherapy regimens.",20966934,GPL570,in situ oligonucleotide,54675,1,50,transformed count,GSE15490,none,data/GEO_v2/datasets/GDS3829.csv,958,agent,5,"{'rituximab': 10, 'fludarabine, cyclophosphamide': 10, 'rituximab, fludarabine, cyclophosphamide': 10, 'control (before rituximab)': 10, 'control (before fludarabine, cyclophosphamide)': 10}","{'rituximab': 1, 'fludarabine, cyclophosphamide': 0, 'rituximab, fludarabine, cyclophosphamide': 1, 'control (before rituximab)': 0, 'control (before fludarabine, cyclophosphamide)': 0}",True
GDS3829,"Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy effect on chronic lymphocytic leukemia","Analysis of CD19+ selected B cells from CLL patients before and after chemoimmunotherapy regimens of rituximab (R), fludarabine and cyclophosphamide (FC), or RFC. Results provide insight into the molecular mechanisms underlying the beneficial effects of the chemoimmunotherapy regimens.",20966934,GPL570,in situ oligonucleotide,54675,1,50,transformed count,GSE15490,none,data/GEO_v2/datasets/GDS3829.csv,958,agent,5,"{'rituximab': 10, 'fludarabine, cyclophosphamide': 10, 'rituximab, fludarabine, cyclophosphamide': 10, 'control (before rituximab)': 10, 'control (before fludarabine, cyclophosphamide)': 10}","{'rituximab': 0, 'fludarabine, cyclophosphamide': 1, 'rituximab, fludarabine, cyclophosphamide': 1, 'control (before rituximab)': 0, 'control (before fludarabine, cyclophosphamide)': 0}",True
GDS3829,"Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy effect on chronic lymphocytic leukemia","Analysis of CD19+ selected B cells from CLL patients before and after chemoimmunotherapy regimens of rituximab (R), fludarabine and cyclophosphamide (FC), or RFC. Results provide insight into the molecular mechanisms underlying the beneficial effects of the chemoimmunotherapy regimens.",20966934,GPL570,in situ oligonucleotide,54675,1,50,transformed count,GSE15490,none,data/GEO_v2/datasets/GDS3829.csv,958,agent,5,"{'rituximab': 10, 'fludarabine, cyclophosphamide': 10, 'rituximab, fludarabine, cyclophosphamide': 10, 'control (before rituximab)': 10, 'control (before fludarabine, cyclophosphamide)': 10}","{'rituximab': 0, 'fludarabine, cyclophosphamide': 0, 'rituximab, fludarabine, cyclophosphamide': 0, 'control (before rituximab)': 1, 'control (before fludarabine, cyclophosphamide)': 1}",True
GDS3057,Acute myeloid leukemia,Comparison of leukemic blasts from 26 acute myeloid leukemia (AML) patients with normal hematopoietic cells at a variety of different stages of maturation from 38 healthy donors. Results provide insight into the possible clinical significance of those genes with AML-specific expression changes.,17910043,GPL96,in situ oligonucleotide,22283,1,64,transformed count,GSE9476,none,data/GEO_v2/datasets/GDS3057.csv,958,disease state,2,"{'normal': 38, 'leukemia': 26}","{'normal': 0, 'leukemia': 1}",True
GDS3057,Acute myeloid leukemia,Comparison of leukemic blasts from 26 acute myeloid leukemia (AML) patients with normal hematopoietic cells at a variety of different stages of maturation from 38 healthy donors. Results provide insight into the possible clinical significance of those genes with AML-specific expression changes.,17910043,GPL96,in situ oligonucleotide,22283,1,64,transformed count,GSE9476,none,data/GEO_v2/datasets/GDS3057.csv,958,cell type,4,"{'peripheral blood': 29, 'bone marrow': 17, 'PBSC CD34plus': 10, 'bone marrow CD34plus': 8}","{'peripheral blood': 0, 'bone marrow': 1, 'PBSC CD34plus': 0, 'bone marrow CD34plus': 1}",True
GDS3057,Acute myeloid leukemia,Comparison of leukemic blasts from 26 acute myeloid leukemia (AML) patients with normal hematopoietic cells at a variety of different stages of maturation from 38 healthy donors. Results provide insight into the possible clinical significance of those genes with AML-specific expression changes.,17910043,GPL96,in situ oligonucleotide,22283,1,64,transformed count,GSE9476,none,data/GEO_v2/datasets/GDS3057.csv,958,cell type,4,"{'peripheral blood': 29, 'bone marrow': 17, 'PBSC CD34plus': 10, 'bone marrow CD34plus': 8}","{'peripheral blood': 0, 'bone marrow': 0, 'PBSC CD34plus': 1, 'bone marrow CD34plus': 1}",True
GDS3885,"Glioblastoma stem-like cell lines, glioblastomas, and glioma cell lines","Analysis of glioblastoma stem-like (GS) cell lines, corresponding glioblastoma primary tumors, conventional glioma cell lines, and GS neurospheres. Results provide insight into cell lines recapitulating transcriptional aspects of glioblastomas, thereby allowing identification of therapeutic targets.","['21294158', '18037961', '25543125']",GPL570,in situ oligonucleotide,54675,1,92,transformed count,GSE23806,none,data/GEO_v2/datasets/GDS3885.csv,958,specimen,7,"{'conventional glioma cell line': 32, 'GSf (full) cell line': 15, 'GSr (restricted) cell line': 12, 'GS primary tumor': 12, 'GSr (restricted) neurosphere': 9, 'GSf (full) neurosphere': 8, 'monolayer culture, ML': 4}","{'conventional glioma cell line': 1, 'GSf (full) cell line': 0, 'GSr (restricted) cell line': 0, 'GS primary tumor': 0, 'GSr (restricted) neurosphere': 0, 'GSf (full) neurosphere': 0, 'monolayer culture, ML': 0}",False
GDS3885,"Glioblastoma stem-like cell lines, glioblastomas, and glioma cell lines","Analysis of glioblastoma stem-like (GS) cell lines, corresponding glioblastoma primary tumors, conventional glioma cell lines, and GS neurospheres. Results provide insight into cell lines recapitulating transcriptional aspects of glioblastomas, thereby allowing identification of therapeutic targets.","['21294158', '18037961', '25543125']",GPL570,in situ oligonucleotide,54675,1,92,transformed count,GSE23806,none,data/GEO_v2/datasets/GDS3885.csv,958,specimen,7,"{'conventional glioma cell line': 32, 'GSf (full) cell line': 15, 'GSr (restricted) cell line': 12, 'GS primary tumor': 12, 'GSr (restricted) neurosphere': 9, 'GSf (full) neurosphere': 8, 'monolayer culture, ML': 4}","{'conventional glioma cell line': 0, 'GSf (full) cell line': 1, 'GSr (restricted) cell line': 1, 'GS primary tumor': 0, 'GSr (restricted) neurosphere': 0, 'GSf (full) neurosphere': 0, 'monolayer culture, ML': 0}",False
GDS3885,"Glioblastoma stem-like cell lines, glioblastomas, and glioma cell lines","Analysis of glioblastoma stem-like (GS) cell lines, corresponding glioblastoma primary tumors, conventional glioma cell lines, and GS neurospheres. Results provide insight into cell lines recapitulating transcriptional aspects of glioblastomas, thereby allowing identification of therapeutic targets.","['21294158', '18037961', '25543125']",GPL570,in situ oligonucleotide,54675,1,92,transformed count,GSE23806,none,data/GEO_v2/datasets/GDS3885.csv,958,specimen,7,"{'conventional glioma cell line': 32, 'GSf (full) cell line': 15, 'GSr (restricted) cell line': 12, 'GS primary tumor': 12, 'GSr (restricted) neurosphere': 9, 'GSf (full) neurosphere': 8, 'monolayer culture, ML': 4}","{'conventional glioma cell line': 0, 'GSf (full) cell line': 0, 'GSr (restricted) cell line': 0, 'GS primary tumor': 1, 'GSr (restricted) neurosphere': 0, 'GSf (full) neurosphere': 0, 'monolayer culture, ML': 0}",False
GDS4358,Two types of HIV-associated neurocognitive impairment: brain regions,"Analysis of basal ganglia, frontal cortex, and white matter from HIV patients with HIV-associated dementia (HAD) or HAD plus HIV encephalitis (HIVE). Results provide insight into molecular events of neurological impairment and inflammation associated with HIV infection in different brain regions.",23049970,GPL570,in situ oligonucleotide,54675,1,72,transformed count,GSE35864,none,data/GEO_v2/datasets/GDS4358.csv,958,disease state,4,"{'HIV + HAD': 21, 'control': 18, 'HIV': 18, 'HIV + HAD + HIVE': 15}","{'HIV + HAD': 0, 'control': 0, 'HIV': 0, 'HIV + HAD + HIVE': 1}",True
GDS4358,Two types of HIV-associated neurocognitive impairment: brain regions,"Analysis of basal ganglia, frontal cortex, and white matter from HIV patients with HIV-associated dementia (HAD) or HAD plus HIV encephalitis (HIVE). Results provide insight into molecular events of neurological impairment and inflammation associated with HIV infection in different brain regions.",23049970,GPL570,in situ oligonucleotide,54675,1,72,transformed count,GSE35864,none,data/GEO_v2/datasets/GDS4358.csv,958,disease state,4,"{'HIV + HAD': 21, 'control': 18, 'HIV': 18, 'HIV + HAD + HIVE': 15}","{'HIV + HAD': 0, 'control': 0, 'HIV': 1, 'HIV + HAD + HIVE': 0}",True
GDS4358,Two types of HIV-associated neurocognitive impairment: brain regions,"Analysis of basal ganglia, frontal cortex, and white matter from HIV patients with HIV-associated dementia (HAD) or HAD plus HIV encephalitis (HIVE). Results provide insight into molecular events of neurological impairment and inflammation associated with HIV infection in different brain regions.",23049970,GPL570,in situ oligonucleotide,54675,1,72,transformed count,GSE35864,none,data/GEO_v2/datasets/GDS4358.csv,958,disease state,4,"{'HIV + HAD': 21, 'control': 18, 'HIV': 18, 'HIV + HAD + HIVE': 15}","{'HIV + HAD': 1, 'control': 0, 'HIV': 0, 'HIV + HAD + HIVE': 0}",True
GDS4358,Two types of HIV-associated neurocognitive impairment: brain regions,"Analysis of basal ganglia, frontal cortex, and white matter from HIV patients with HIV-associated dementia (HAD) or HAD plus HIV encephalitis (HIVE). Results provide insight into molecular events of neurological impairment and inflammation associated with HIV infection in different brain regions.",23049970,GPL570,in situ oligonucleotide,54675,1,72,transformed count,GSE35864,none,data/GEO_v2/datasets/GDS4358.csv,958,tissue,3,"{'Basal ganglia': 24, 'Frontal cortex': 24, 'White matter': 24}","{'Basal ganglia': 0, 'Frontal cortex': 0, 'White matter': 1}",True
GDS4358,Two types of HIV-associated neurocognitive impairment: brain regions,"Analysis of basal ganglia, frontal cortex, and white matter from HIV patients with HIV-associated dementia (HAD) or HAD plus HIV encephalitis (HIVE). Results provide insight into molecular events of neurological impairment and inflammation associated with HIV infection in different brain regions.",23049970,GPL570,in situ oligonucleotide,54675,1,72,transformed count,GSE35864,none,data/GEO_v2/datasets/GDS4358.csv,958,tissue,3,"{'Basal ganglia': 24, 'Frontal cortex': 24, 'White matter': 24}","{'Basal ganglia': 0, 'Frontal cortex': 1, 'White matter': 0}",True
GDS4358,Two types of HIV-associated neurocognitive impairment: brain regions,"Analysis of basal ganglia, frontal cortex, and white matter from HIV patients with HIV-associated dementia (HAD) or HAD plus HIV encephalitis (HIVE). Results provide insight into molecular events of neurological impairment and inflammation associated with HIV infection in different brain regions.",23049970,GPL570,in situ oligonucleotide,54675,1,72,transformed count,GSE35864,none,data/GEO_v2/datasets/GDS4358.csv,958,tissue,3,"{'Basal ganglia': 24, 'Frontal cortex': 24, 'White matter': 24}","{'Basal ganglia': 1, 'Frontal cortex': 0, 'White matter': 0}",True
GDS4906,Exercise training effect on chronic obstructive pulmonary disease patients: vastus lateralis muscle,Analysis of muscle from chronic obstructive pulmonary disease (COPD) patients before and after 8 weeks of exercise training. Skeletal muscle dysfunction and muscle wasting are hallmark systemic effects of COPD. Results provide insight into molecular mechanisms underlying COPD muscle degeneration.,21909251,GPL570,in situ oligonucleotide,54675,1,54,transformed count,GSE27536,none,data/GEO_v2/datasets/GDS4906.csv,958,disease state,2,"{'chronic obstructive pulmonary disease': 30, 'healthy': 24}","{'chronic obstructive pulmonary disease': 0, 'healthy': 1}",True
GDS4906,Exercise training effect on chronic obstructive pulmonary disease patients: vastus lateralis muscle,Analysis of muscle from chronic obstructive pulmonary disease (COPD) patients before and after 8 weeks of exercise training. Skeletal muscle dysfunction and muscle wasting are hallmark systemic effects of COPD. Results provide insight into molecular mechanisms underlying COPD muscle degeneration.,21909251,GPL570,in situ oligonucleotide,54675,1,54,transformed count,GSE27536,none,data/GEO_v2/datasets/GDS4906.csv,958,protocol,2,"{'sedentary': 27, 'exercise trained': 27}","{'sedentary': 0, 'exercise trained': 1}",True
GDS4906,Exercise training effect on chronic obstructive pulmonary disease patients: vastus lateralis muscle,Analysis of muscle from chronic obstructive pulmonary disease (COPD) patients before and after 8 weeks of exercise training. Skeletal muscle dysfunction and muscle wasting are hallmark systemic effects of COPD. Results provide insight into molecular mechanisms underlying COPD muscle degeneration.,21909251,GPL570,in situ oligonucleotide,54675,1,54,transformed count,GSE27536,none,data/GEO_v2/datasets/GDS4906.csv,958,other,2,"{'BMI: normal': 42, 'BMI: low': 12}","{'BMI: normal': 0, 'BMI: low': 1}",True
GDS3459,Frontotemporal lobar degeneration with ubiquitinated inclusions and progranulin mutations: various brain regions,Analysis of various brain regions of patients who suffered from frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U). Presence of progranulin (GRN) mutations determined. GRN mutations are associated with FTLD-U. Results identify expression signatures for GRN subtypes of FTLD-U.,18223198,GPL571,in situ oligonucleotide,22277,1,56,transformed count,GSE13162,none,data/GEO_v2/datasets/GDS3459.csv,958,disease state,3,"{'FTLD-U without progranulin mutation': 24, 'control': 17, 'FTLD-U with progranulin mutation': 15}","{'FTLD-U without progranulin mutation': 0, 'control': 1, 'FTLD-U with progranulin mutation': 0}",False
GDS3459,Frontotemporal lobar degeneration with ubiquitinated inclusions and progranulin mutations: various brain regions,Analysis of various brain regions of patients who suffered from frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U). Presence of progranulin (GRN) mutations determined. GRN mutations are associated with FTLD-U. Results identify expression signatures for GRN subtypes of FTLD-U.,18223198,GPL571,in situ oligonucleotide,22277,1,56,transformed count,GSE13162,none,data/GEO_v2/datasets/GDS3459.csv,958,tissue,3,"{'frontal': 24, 'cerebellum': 17, 'hippocampus': 15}","{'frontal': 0, 'cerebellum': 0, 'hippocampus': 1}",False
GDS3459,Frontotemporal lobar degeneration with ubiquitinated inclusions and progranulin mutations: various brain regions,Analysis of various brain regions of patients who suffered from frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U). Presence of progranulin (GRN) mutations determined. GRN mutations are associated with FTLD-U. Results identify expression signatures for GRN subtypes of FTLD-U.,18223198,GPL571,in situ oligonucleotide,22277,1,56,transformed count,GSE13162,none,data/GEO_v2/datasets/GDS3459.csv,958,tissue,3,"{'frontal': 24, 'cerebellum': 17, 'hippocampus': 15}","{'frontal': 0, 'cerebellum': 1, 'hippocampus': 0}",False
GDS3459,Frontotemporal lobar degeneration with ubiquitinated inclusions and progranulin mutations: various brain regions,Analysis of various brain regions of patients who suffered from frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U). Presence of progranulin (GRN) mutations determined. GRN mutations are associated with FTLD-U. Results identify expression signatures for GRN subtypes of FTLD-U.,18223198,GPL571,in situ oligonucleotide,22277,1,56,transformed count,GSE13162,none,data/GEO_v2/datasets/GDS3459.csv,958,tissue,3,"{'frontal': 24, 'cerebellum': 17, 'hippocampus': 15}","{'frontal': 1, 'cerebellum': 0, 'hippocampus': 0}",False
GDS3257,Cigarette smoking effect on lung adenocarcinoma,"Analysis of different tumor stage adenocarcinoma and paired normal lung tissues of current, former and never smokers. To date, tobacco smoking is responsible for over 90% of lung cancers. Results provide insight into the molecular basis of lung carcinogenesis induced by smoking.",18297132,GPL96,in situ oligonucleotide,22283,1,107,transformed count,GSE10072,none,data/GEO_v2/datasets/GDS3257.csv,958,tissue,2,"{'tumor': 58, 'normal': 49}","{'tumor': 0, 'normal': 1}",False
GDS3257,Cigarette smoking effect on lung adenocarcinoma,"Analysis of different tumor stage adenocarcinoma and paired normal lung tissues of current, former and never smokers. To date, tobacco smoking is responsible for over 90% of lung cancers. Results provide insight into the molecular basis of lung carcinogenesis induced by smoking.",18297132,GPL96,in situ oligonucleotide,22283,1,107,transformed count,GSE10072,none,data/GEO_v2/datasets/GDS3257.csv,958,individual,3,"{'current smoker': 40, 'former smoker': 36, 'never smoker': 31}","{'current smoker': 0, 'former smoker': 0, 'never smoker': 1}",False
GDS3257,Cigarette smoking effect on lung adenocarcinoma,"Analysis of different tumor stage adenocarcinoma and paired normal lung tissues of current, former and never smokers. To date, tobacco smoking is responsible for over 90% of lung cancers. Results provide insight into the molecular basis of lung carcinogenesis induced by smoking.",18297132,GPL96,in situ oligonucleotide,22283,1,107,transformed count,GSE10072,none,data/GEO_v2/datasets/GDS3257.csv,958,gender,2,"{'male': 69, 'female': 38}","{'male': 0, 'female': 1}",False
GDS3257,Cigarette smoking effect on lung adenocarcinoma,"Analysis of different tumor stage adenocarcinoma and paired normal lung tissues of current, former and never smokers. To date, tobacco smoking is responsible for over 90% of lung cancers. Results provide insight into the molecular basis of lung carcinogenesis induced by smoking.",18297132,GPL96,in situ oligonucleotide,22283,1,107,transformed count,GSE10072,none,data/GEO_v2/datasets/GDS3257.csv,958,other,2,"{'early stage tumor tissue': 80, 'late stage tumor tissue': 27}","{'early stage tumor tissue': 0, 'late stage tumor tissue': 1}",False
GDS3837,Non-small cell lung carcinoma in female nonsmokers,Analysis of paired tumor and adjacent normal lung tissue specimens obtained from nonsmoking female non-small cell lung carcinoma (NSCLC) patients in Taiwan. Results provide insight into potential prognostic biomarkers and therapeutic targets for NSCLC.,20802022,GPL570,in situ oligonucleotide,54675,1,120,transformed count,GSE19804,none,data/GEO_v2/datasets/GDS3837.csv,958,disease state,2,"{'lung cancer': 60, 'control': 60}","{'lung cancer': 0, 'control': 1}",True
GDS5093,Acute Dengue patients: whole blood,Analysis of blood from patients with acute Dengue virus (DENV) infection and during convalescence. Dengue is a mosquito-borne infectious disease and Dengue Hemorrhagic Fever is a life-threatening illness. Results provide insight into molecular mechanisms underlying host response to DENV infection.,24981333,GPL13158,in situ oligonucleotide,54715,1,56,transformed count,GSE51808,none,data/GEO_v2/datasets/GDS5093.csv,975,infection,2,"{'Dengue virus': 47, 'control': 9}","{'Dengue virus': 0, 'control': 1}",False
GDS5093,Acute Dengue patients: whole blood,Analysis of blood from patients with acute Dengue virus (DENV) infection and during convalescence. Dengue is a mosquito-borne infectious disease and Dengue Hemorrhagic Fever is a life-threatening illness. Results provide insight into molecular mechanisms underlying host response to DENV infection.,24981333,GPL13158,in situ oligonucleotide,54715,1,56,transformed count,GSE51808,none,data/GEO_v2/datasets/GDS5093.csv,975,disease state,4,"{'Convalescent': 19, 'Dengue Fever': 18, 'Dengue Hemorrhagic Fever': 10, 'healthy control': 9}","{'Convalescent': 1, 'Dengue Fever': 0, 'Dengue Hemorrhagic Fever': 0, 'healthy control': 0}",False
GDS5093,Acute Dengue patients: whole blood,Analysis of blood from patients with acute Dengue virus (DENV) infection and during convalescence. Dengue is a mosquito-borne infectious disease and Dengue Hemorrhagic Fever is a life-threatening illness. Results provide insight into molecular mechanisms underlying host response to DENV infection.,24981333,GPL13158,in situ oligonucleotide,54715,1,56,transformed count,GSE51808,none,data/GEO_v2/datasets/GDS5093.csv,975,disease state,4,"{'Convalescent': 19, 'Dengue Fever': 18, 'Dengue Hemorrhagic Fever': 10, 'healthy control': 9}","{'Convalescent': 0, 'Dengue Fever': 1, 'Dengue Hemorrhagic Fever': 1, 'healthy control': 0}",False
GDS3952,Breast cancer patients: peripheral blood mononuclear cells,"Analysis of PBMCs from breast cancer patients, patients with benign breast abnormalities, healthy individuals, and patients with other types of cancer (GI, brain). These results, together with results from a murine breast cancer model, provide insight into developing a human breast tumor predictor.",21781289,GPL570,in situ oligonucleotide,54675,1,162,transformed count,GSE27567,none,data/GEO_v2/datasets/GDS3952.csv,958,disease state,6,"{'malignant breast cancer': 51, 'benign breast abnormalities': 37, 'healthy': 31, 'ectopic (gastrointestinal and brain) cancers': 22, 'Post-Surgery (malignant)': 15, 'Pre-Surgery (malignant)': 6}","{'malignant breast cancer': 1, 'benign breast abnormalities': 0, 'healthy': 0, 'ectopic (gastrointestinal and brain) cancers': 0, 'Post-Surgery (malignant)': 0, 'Pre-Surgery (malignant)': 0}",False
GDS3952,Breast cancer patients: peripheral blood mononuclear cells,"Analysis of PBMCs from breast cancer patients, patients with benign breast abnormalities, healthy individuals, and patients with other types of cancer (GI, brain). These results, together with results from a murine breast cancer model, provide insight into developing a human breast tumor predictor.",21781289,GPL570,in situ oligonucleotide,54675,1,162,transformed count,GSE27567,none,data/GEO_v2/datasets/GDS3952.csv,958,disease state,6,"{'malignant breast cancer': 51, 'benign breast abnormalities': 37, 'healthy': 31, 'ectopic (gastrointestinal and brain) cancers': 22, 'Post-Surgery (malignant)': 15, 'Pre-Surgery (malignant)': 6}","{'malignant breast cancer': 0, 'benign breast abnormalities': 1, 'healthy': 1, 'ectopic (gastrointestinal and brain) cancers': 0, 'Post-Surgery (malignant)': 0, 'Pre-Surgery (malignant)': 0}",False
GDS3952,Breast cancer patients: peripheral blood mononuclear cells,"Analysis of PBMCs from breast cancer patients, patients with benign breast abnormalities, healthy individuals, and patients with other types of cancer (GI, brain). These results, together with results from a murine breast cancer model, provide insight into developing a human breast tumor predictor.",21781289,GPL570,in situ oligonucleotide,54675,1,162,transformed count,GSE27567,none,data/GEO_v2/datasets/GDS3952.csv,958,disease state,6,"{'malignant breast cancer': 51, 'benign breast abnormalities': 37, 'healthy': 31, 'ectopic (gastrointestinal and brain) cancers': 22, 'Post-Surgery (malignant)': 15, 'Pre-Surgery (malignant)': 6}","{'malignant breast cancer': 0, 'benign breast abnormalities': 0, 'healthy': 0, 'ectopic (gastrointestinal and brain) cancers': 1, 'Post-Surgery (malignant)': 0, 'Pre-Surgery (malignant)': 0}",False
GDS4549,Pulmonary fibrosis with associated pulmonary hypertension: lung explants,"Analysis of lung from pulmonary fibrosis (PF) patients divided into different groups based on the mean pulmonary arterial pressure (mPAP): severe pulmonary hypertension (PH) group, intermediate PH group, NoPH group. Results provide insight into the pathobiology of PF with associated PH.",21835902,GPL6244,in situ oligonucleotide,33297,1,116,transformed count,GSE24988,none,data/GEO_v2/datasets/GDS4549.csv,959,disease state,4,"{'PF + intermediate PH': 45, 'PH validation set': 32, 'PF + no PH': 22, 'PF + severe PH': 17}","{'PF + intermediate PH': 0, 'PH validation set': 0, 'PF + no PH': 0, 'PF + severe PH': 1}",False
GDS4549,Pulmonary fibrosis with associated pulmonary hypertension: lung explants,"Analysis of lung from pulmonary fibrosis (PF) patients divided into different groups based on the mean pulmonary arterial pressure (mPAP): severe pulmonary hypertension (PH) group, intermediate PH group, NoPH group. Results provide insight into the pathobiology of PF with associated PH.",21835902,GPL6244,in situ oligonucleotide,33297,1,116,transformed count,GSE24988,none,data/GEO_v2/datasets/GDS4549.csv,959,disease state,4,"{'PF + intermediate PH': 45, 'PH validation set': 32, 'PF + no PH': 22, 'PF + severe PH': 17}","{'PF + intermediate PH': 0, 'PH validation set': 0, 'PF + no PH': 1, 'PF + severe PH': 0}",False
GDS4549,Pulmonary fibrosis with associated pulmonary hypertension: lung explants,"Analysis of lung from pulmonary fibrosis (PF) patients divided into different groups based on the mean pulmonary arterial pressure (mPAP): severe pulmonary hypertension (PH) group, intermediate PH group, NoPH group. Results provide insight into the pathobiology of PF with associated PH.",21835902,GPL6244,in situ oligonucleotide,33297,1,116,transformed count,GSE24988,none,data/GEO_v2/datasets/GDS4549.csv,959,disease state,4,"{'PF + intermediate PH': 45, 'PH validation set': 32, 'PF + no PH': 22, 'PF + severe PH': 17}","{'PF + intermediate PH': 1, 'PH validation set': 0, 'PF + no PH': 0, 'PF + severe PH': 0}",False
GDS4471,Medulloblastomas in children,Analysis of medulloblastomas from children ages 3 to 16 years. Medulloblastoma is a malignant childhood brain tumor comprising four discrete subgroups. Results provide insights into pathogenesis of medulloblastoma and highlight targets for therapeutic development.,22722829,GPL570,in situ oligonucleotide,54675,1,76,transformed count,GSE37418,none,data/GEO_v2/datasets/GDS4471.csv,958,disease state,6,"{'subgroup: G4': 39, 'subgroup: G3': 16, 'subgroup: SHH': 10, 'subgroup: WNT': 8, 'subgroup: N/A': 2, 'subgroup: SHH outlier': 1}","{'subgroup: G4': 0, 'subgroup: G3': 0, 'subgroup: SHH': 0, 'subgroup: WNT': 1, 'subgroup: N/A': 0, 'subgroup: SHH outlier': 0}",True
GDS4471,Medulloblastomas in children,Analysis of medulloblastomas from children ages 3 to 16 years. Medulloblastoma is a malignant childhood brain tumor comprising four discrete subgroups. Results provide insights into pathogenesis of medulloblastoma and highlight targets for therapeutic development.,22722829,GPL570,in situ oligonucleotide,54675,1,76,transformed count,GSE37418,none,data/GEO_v2/datasets/GDS4471.csv,958,disease state,6,"{'subgroup: G4': 39, 'subgroup: G3': 16, 'subgroup: SHH': 10, 'subgroup: WNT': 8, 'subgroup: N/A': 2, 'subgroup: SHH outlier': 1}","{'subgroup: G4': 0, 'subgroup: G3': 0, 'subgroup: SHH': 1, 'subgroup: WNT': 0, 'subgroup: N/A': 0, 'subgroup: SHH outlier': 1}",True
GDS4471,Medulloblastomas in children,Analysis of medulloblastomas from children ages 3 to 16 years. Medulloblastoma is a malignant childhood brain tumor comprising four discrete subgroups. Results provide insights into pathogenesis of medulloblastoma and highlight targets for therapeutic development.,22722829,GPL570,in situ oligonucleotide,54675,1,76,transformed count,GSE37418,none,data/GEO_v2/datasets/GDS4471.csv,958,disease state,6,"{'subgroup: G4': 39, 'subgroup: G3': 16, 'subgroup: SHH': 10, 'subgroup: WNT': 8, 'subgroup: N/A': 2, 'subgroup: SHH outlier': 1}","{'subgroup: G4': 0, 'subgroup: G3': 1, 'subgroup: SHH': 0, 'subgroup: WNT': 0, 'subgroup: N/A': 0, 'subgroup: SHH outlier': 0}",True
GDS4471,Medulloblastomas in children,Analysis of medulloblastomas from children ages 3 to 16 years. Medulloblastoma is a malignant childhood brain tumor comprising four discrete subgroups. Results provide insights into pathogenesis of medulloblastoma and highlight targets for therapeutic development.,22722829,GPL570,in situ oligonucleotide,54675,1,76,transformed count,GSE37418,none,data/GEO_v2/datasets/GDS4471.csv,958,disease state,6,"{'subgroup: G4': 39, 'subgroup: G3': 16, 'subgroup: SHH': 10, 'subgroup: WNT': 8, 'subgroup: N/A': 2, 'subgroup: SHH outlier': 1}","{'subgroup: G4': 0, 'subgroup: G3': 1, 'subgroup: SHH': 1, 'subgroup: WNT': 1, 'subgroup: N/A': 1, 'subgroup: SHH outlier': 1}",True
GDS4471,Medulloblastomas in children,Analysis of medulloblastomas from children ages 3 to 16 years. Medulloblastoma is a malignant childhood brain tumor comprising four discrete subgroups. Results provide insights into pathogenesis of medulloblastoma and highlight targets for therapeutic development.,22722829,GPL570,in situ oligonucleotide,54675,1,76,transformed count,GSE37418,none,data/GEO_v2/datasets/GDS4471.csv,958,gender,2,"{'male': 54, 'female': 22}","{'male': 0, 'female': 1}",True
GDS5037,Severe asthma: bronchial epithelial cell,Analysis of bronchial epithelial cells from patients with severe asthma. Results provide insight into the molecular mechanisms underlying the development of severe asthma.,24518246,GPL6480,in situ oligonucleotide,41108,1,108,transformed count,GSE43696,none,data/GEO_v2/datasets/GDS5037.csv,972,disease state,3,"{'mild asthma': 50, 'severe asthma': 38, 'control': 20}","{'mild asthma': 0, 'severe asthma': 0, 'control': 1}",True
GDS5037,Severe asthma: bronchial epithelial cell,Analysis of bronchial epithelial cells from patients with severe asthma. Results provide insight into the molecular mechanisms underlying the development of severe asthma.,24518246,GPL6480,in situ oligonucleotide,41108,1,108,transformed count,GSE43696,none,data/GEO_v2/datasets/GDS5037.csv,972,disease state,3,"{'mild asthma': 50, 'severe asthma': 38, 'control': 20}","{'mild asthma': 0, 'severe asthma': 1, 'control': 0}",True
GDS5037,Severe asthma: bronchial epithelial cell,Analysis of bronchial epithelial cells from patients with severe asthma. Results provide insight into the molecular mechanisms underlying the development of severe asthma.,24518246,GPL6480,in situ oligonucleotide,41108,1,108,transformed count,GSE43696,none,data/GEO_v2/datasets/GDS5037.csv,972,disease state,3,"{'mild asthma': 50, 'severe asthma': 38, 'control': 20}","{'mild asthma': 1, 'severe asthma': 0, 'control': 0}",True
GDS5037,Severe asthma: bronchial epithelial cell,Analysis of bronchial epithelial cells from patients with severe asthma. Results provide insight into the molecular mechanisms underlying the development of severe asthma.,24518246,GPL6480,in situ oligonucleotide,41108,1,108,transformed count,GSE43696,none,data/GEO_v2/datasets/GDS5037.csv,972,gender,2,"{'female': 74, 'male': 34}","{'female': 0, 'male': 1}",True
GDS4274,Stratification of pediatric septic shock patients: whole blood,Analysis of whole blood from children (up to 10 years old) within 24hrs of PICU admission for septic shock. Heterogeneous clinical phenotypes stratify the septic shock patients. Results provide insight into the molecular mechanisms underlying these septic shock subgroups.,"['19624809', '21738952']",GPL570,in situ oligonucleotide,54675,1,130,transformed count,GSE26440,none,data/GEO_v2/datasets/GDS4274.csv,958,disease state,2,"{'septic shock': 98, 'healthy control': 32}","{'septic shock': 0, 'healthy control': 1}",True
GDS4299,Early T-cell precursor acute lymphoblastic leukemia,Analysis of tumor cells from pediatric patients with early T-cell precursor acute lymphoblastic leukemia (ETP ALL). The ETP ALL subtype has a poor prognosis when treated with standard chemotherapy. Results provide insight into the molecular mechanisms underlying ETP ALL.,"['22237106', '21878675']",GPL13158,in situ oligonucleotide,54715,1,52,transformed count,GSE28703,none,data/GEO_v2/datasets/GDS4299.csv,975,disease state,2,"{'non-ETP ALL': 40, 'ETP ALL': 12}","{'non-ETP ALL': 0, 'ETP ALL': 1}",False
GDS4278,Acute myeloid leukemia with CEBPA mutations [AMLSG cohort]: mononuclear cells,Analysis of mononuclear cells from bone marrow of untreated AML patients with CCAAT/enhancer binding protein alpha double mutation (CEBPAdm) or single mutation (CEBPAsm). Favorable outcome is observed in AML patients with CEBPAdm. Results provide insight into molecular basis of AML classification.,21177436,GPL570,in situ oligonucleotide,54675,1,154,transformed count,GSE22845,none,data/GEO_v2/datasets/GDS4278.csv,958,genotype/variation,3,"{'CEBPAwt': 132, 'CEBPAdm': 16, 'CEBPAsm': 6}","{'CEBPAwt': 0, 'CEBPAdm': 1, 'CEBPAsm': 1}",False
GDS4266,Tolerant renal transplant recipients: peripheral whole blood,"Analysis of whole blood from tolerant renal transplant recipients (i.e., with stable graft function and receiving no immunosuppressive drugs for >1 year) and from recipients stable on immunosuppressive drugs. Results provide insight into molecular mechanisms underlying renal transplant tolerance.",20501946,GPL570,in situ oligonucleotide,54675,1,58,transformed count,GSE22229,none,data/GEO_v2/datasets/GDS4266.csv,958,individual,3,"{'Standard Immunotherapy': 27, 'Tolerant': 19, 'Healthy control': 12}","{'Standard Immunotherapy': 0, 'Tolerant': 0, 'Healthy control': 1}",True
GDS4266,Tolerant renal transplant recipients: peripheral whole blood,"Analysis of whole blood from tolerant renal transplant recipients (i.e., with stable graft function and receiving no immunosuppressive drugs for >1 year) and from recipients stable on immunosuppressive drugs. Results provide insight into molecular mechanisms underlying renal transplant tolerance.",20501946,GPL570,in situ oligonucleotide,54675,1,58,transformed count,GSE22229,none,data/GEO_v2/datasets/GDS4266.csv,958,individual,3,"{'Standard Immunotherapy': 27, 'Tolerant': 19, 'Healthy control': 12}","{'Standard Immunotherapy': 0, 'Tolerant': 1, 'Healthy control': 0}",True
GDS4266,Tolerant renal transplant recipients: peripheral whole blood,"Analysis of whole blood from tolerant renal transplant recipients (i.e., with stable graft function and receiving no immunosuppressive drugs for >1 year) and from recipients stable on immunosuppressive drugs. Results provide insight into molecular mechanisms underlying renal transplant tolerance.",20501946,GPL570,in situ oligonucleotide,54675,1,58,transformed count,GSE22229,none,data/GEO_v2/datasets/GDS4266.csv,958,individual,3,"{'Standard Immunotherapy': 27, 'Tolerant': 19, 'Healthy control': 12}","{'Standard Immunotherapy': 1, 'Tolerant': 0, 'Healthy control': 0}",True
GDS4130,Endoplasmic reticulum stress effect on lymphoblastoid cells of monozygotic twins,"Analysis of immortalized B cells from MZ twin pairs (14 of European ancestry, 12 African American) treated in vitro with thapsigargin to induce ER stress.  ER stress induces the unfolded protein response (UPR). Results provide insight into the molecular basis of the UPR response within twin pairs.",20398888,GPL570,in situ oligonucleotide,54675,1,104,transformed count,GSE19519,none,data/GEO_v2/datasets/GDS4130.csv,958,agent,2,"{'control': 52, 'thapsigargin': 52}","{'control': 0, 'thapsigargin': 1}",True
GDS4130,Endoplasmic reticulum stress effect on lymphoblastoid cells of monozygotic twins,"Analysis of immortalized B cells from MZ twin pairs (14 of European ancestry, 12 African American) treated in vitro with thapsigargin to induce ER stress.  ER stress induces the unfolded protein response (UPR). Results provide insight into the molecular basis of the UPR response within twin pairs.",20398888,GPL570,in situ oligonucleotide,54675,1,104,transformed count,GSE19519,none,data/GEO_v2/datasets/GDS4130.csv,958,genotype/variation,2,"{'European ancestry': 56, 'African American ancestry': 48}","{'European ancestry': 0, 'African American ancestry': 1}",True
GDS5000,Mechanistic Indicators of Asthma (MICA) cohort: peripheral blood,"Analysis of peripheral blood from asthmatic and non-asthmatic children (ages 9 to 13), participants of the MICA study conducted by the EPA from 11/2006 to 01/2007 in Detroit, MI. These results, together with clinical biomarker measurements, may help to differentiate asthmatics from non-asthmatics.","['24188919', '25643280']",GPL570,in situ oligonucleotide,54675,1,131,transformed count,GSE35571,none,data/GEO_v2/datasets/GDS5000.csv,958,disease state,3,"{'non-asthmatic': 64, 'asthmatic': 60, 'nan': 7}","{'non-asthmatic': 0, 'asthmatic': 1, 'nan': 0}",False
GDS5000,Mechanistic Indicators of Asthma (MICA) cohort: peripheral blood,"Analysis of peripheral blood from asthmatic and non-asthmatic children (ages 9 to 13), participants of the MICA study conducted by the EPA from 11/2006 to 01/2007 in Detroit, MI. These results, together with clinical biomarker measurements, may help to differentiate asthmatics from non-asthmatics.","['24188919', '25643280']",GPL570,in situ oligonucleotide,54675,1,131,transformed count,GSE35571,none,data/GEO_v2/datasets/GDS5000.csv,958,gender,2,"{'male': 78, 'female': 53}","{'male': 0, 'female': 1}",False
GDS4602,Psoriasis lesional and non-lesional skin,"Analysis of skin punch biopsies from lesional skin (involved sample) and non-lesional skin (uninvolved sample) from each psoriatic patient. Psoriasis is an immune-mediated, inflammatory and hyperproliferative disease of skin and joints. Results provide insight into the molecular basis of psoriasis.","['19169254', '21483750']",GPL570,in situ oligonucleotide,54675,1,180,transformed count,GSE13355,none,data/GEO_v2/datasets/GDS4602.csv,958,disease state,2,"{'psoriasis': 116, 'healthy': 64}","{'psoriasis': 0, 'healthy': 1}",True
GDS2643,Waldenstrom's macroglobulinemia: B lymphocytes and plasma cells,"Analysis of B lymphocytes (BL) and plasma cells (PC) from patients with Waldenstrom's macroglobulinemia (WM), a B-lymphoproliferative disorder (BLPD). Results provide insight into differences between PC and BL from WM and their cell counterpart in chronic lymphocytic leukemia and multiple myeloma.",17252022,GPL96,in situ oligonucleotide,22283,1,56,transformed count,GSE6691,none,data/GEO_v2/datasets/GDS2643.csv,958,disease state,4,"{""Waldenstrom's macroglobulinemia"": 20, 'normal': 13, 'multiple myeloma': 12, 'chronic lymphocytic leukemia': 11}","{""Waldenstrom's macroglobulinemia"": 0, 'normal': 0, 'multiple myeloma': 0, 'chronic lymphocytic leukemia': 1}",True
GDS2643,Waldenstrom's macroglobulinemia: B lymphocytes and plasma cells,"Analysis of B lymphocytes (BL) and plasma cells (PC) from patients with Waldenstrom's macroglobulinemia (WM), a B-lymphoproliferative disorder (BLPD). Results provide insight into differences between PC and BL from WM and their cell counterpart in chronic lymphocytic leukemia and multiple myeloma.",17252022,GPL96,in situ oligonucleotide,22283,1,56,transformed count,GSE6691,none,data/GEO_v2/datasets/GDS2643.csv,958,disease state,4,"{""Waldenstrom's macroglobulinemia"": 20, 'normal': 13, 'multiple myeloma': 12, 'chronic lymphocytic leukemia': 11}","{""Waldenstrom's macroglobulinemia"": 0, 'normal': 0, 'multiple myeloma': 1, 'chronic lymphocytic leukemia': 0}",True
GDS2643,Waldenstrom's macroglobulinemia: B lymphocytes and plasma cells,"Analysis of B lymphocytes (BL) and plasma cells (PC) from patients with Waldenstrom's macroglobulinemia (WM), a B-lymphoproliferative disorder (BLPD). Results provide insight into differences between PC and BL from WM and their cell counterpart in chronic lymphocytic leukemia and multiple myeloma.",17252022,GPL96,in situ oligonucleotide,22283,1,56,transformed count,GSE6691,none,data/GEO_v2/datasets/GDS2643.csv,958,disease state,4,"{""Waldenstrom's macroglobulinemia"": 20, 'normal': 13, 'multiple myeloma': 12, 'chronic lymphocytic leukemia': 11}","{""Waldenstrom's macroglobulinemia"": 0, 'normal': 1, 'multiple myeloma': 0, 'chronic lymphocytic leukemia': 0}",True
GDS2643,Waldenstrom's macroglobulinemia: B lymphocytes and plasma cells,"Analysis of B lymphocytes (BL) and plasma cells (PC) from patients with Waldenstrom's macroglobulinemia (WM), a B-lymphoproliferative disorder (BLPD). Results provide insight into differences between PC and BL from WM and their cell counterpart in chronic lymphocytic leukemia and multiple myeloma.",17252022,GPL96,in situ oligonucleotide,22283,1,56,transformed count,GSE6691,none,data/GEO_v2/datasets/GDS2643.csv,958,disease state,4,"{""Waldenstrom's macroglobulinemia"": 20, 'normal': 13, 'multiple myeloma': 12, 'chronic lymphocytic leukemia': 11}","{""Waldenstrom's macroglobulinemia"": 1, 'normal': 0, 'multiple myeloma': 0, 'chronic lymphocytic leukemia': 0}",True
GDS2643,Waldenstrom's macroglobulinemia: B lymphocytes and plasma cells,"Analysis of B lymphocytes (BL) and plasma cells (PC) from patients with Waldenstrom's macroglobulinemia (WM), a B-lymphoproliferative disorder (BLPD). Results provide insight into differences between PC and BL from WM and their cell counterpart in chronic lymphocytic leukemia and multiple myeloma.",17252022,GPL96,in situ oligonucleotide,22283,1,56,transformed count,GSE6691,none,data/GEO_v2/datasets/GDS2643.csv,958,cell type,2,"{'B lymphocyte': 29, 'plasma cell': 27}","{'B lymphocyte': 0, 'plasma cell': 1}",True
GDS5499,Pulmonary hypertensions: PBMCs,"Analysis of PBMCs from patients with idiopathic pulmonary arterial hypertension (IPAH), systemic sclerosis (SSc), SSc associated PAH (SSc-PAH), and SSc complicated by interstitial lung disease and PH (SSc-PH-ILD). Results provide insight into the molecular basis of the various disease groups.",22545094,GPL6947,oligonucleotide beads,49576,1,140,transformed count,GSE33463,none,data/GEO_v2/datasets/GDS5499.csv,965,disease state,5,"{'scleroderma-associated pulmonary arterial hypertension': 42, 'control': 41, 'idiopathic pulmonary arterial hypertension': 30, 'systemic sclerosis without pulmonary hypertension': 19, 'systemic sclerosis SSc complicated by interstitial lung disease and pulmonary hypertension': 8}","{'scleroderma-associated pulmonary arterial hypertension': 0, 'control': 1, 'idiopathic pulmonary arterial hypertension': 0, 'systemic sclerosis without pulmonary hypertension': 1, 'systemic sclerosis SSc complicated by interstitial lung disease and pulmonary hypertension': 0}",True
GDS5499,Pulmonary hypertensions: PBMCs,"Analysis of PBMCs from patients with idiopathic pulmonary arterial hypertension (IPAH), systemic sclerosis (SSc), SSc associated PAH (SSc-PAH), and SSc complicated by interstitial lung disease and PH (SSc-PH-ILD). Results provide insight into the molecular basis of the various disease groups.",22545094,GPL6947,oligonucleotide beads,49576,1,140,transformed count,GSE33463,none,data/GEO_v2/datasets/GDS5499.csv,965,disease state,5,"{'scleroderma-associated pulmonary arterial hypertension': 42, 'control': 41, 'idiopathic pulmonary arterial hypertension': 30, 'systemic sclerosis without pulmonary hypertension': 19, 'systemic sclerosis SSc complicated by interstitial lung disease and pulmonary hypertension': 8}","{'scleroderma-associated pulmonary arterial hypertension': 0, 'control': 1, 'idiopathic pulmonary arterial hypertension': 0, 'systemic sclerosis without pulmonary hypertension': 0, 'systemic sclerosis SSc complicated by interstitial lung disease and pulmonary hypertension': 0}",True
GDS5499,Pulmonary hypertensions: PBMCs,"Analysis of PBMCs from patients with idiopathic pulmonary arterial hypertension (IPAH), systemic sclerosis (SSc), SSc associated PAH (SSc-PAH), and SSc complicated by interstitial lung disease and PH (SSc-PH-ILD). Results provide insight into the molecular basis of the various disease groups.",22545094,GPL6947,oligonucleotide beads,49576,1,140,transformed count,GSE33463,none,data/GEO_v2/datasets/GDS5499.csv,965,disease state,5,"{'scleroderma-associated pulmonary arterial hypertension': 42, 'control': 41, 'idiopathic pulmonary arterial hypertension': 30, 'systemic sclerosis without pulmonary hypertension': 19, 'systemic sclerosis SSc complicated by interstitial lung disease and pulmonary hypertension': 8}","{'scleroderma-associated pulmonary arterial hypertension': 0, 'control': 0, 'idiopathic pulmonary arterial hypertension': 0, 'systemic sclerosis without pulmonary hypertension': 1, 'systemic sclerosis SSc complicated by interstitial lung disease and pulmonary hypertension': 1}",True
GDS5083,Carotid artery atheroma,Analysis of carotid artery atheromatous plaques from hypertensive patients. Atheromas are fatty deposits in the walls of arteries. Results provide insight into the molecular pathogenesis of atheroma.,23660665,GPL6244,in situ oligonucleotide,33297,1,64,transformed count,GSE43292,none,data/GEO_v2/datasets/GDS5083.csv,959,specimen,2,"{'atheroma plaque': 32, 'adjacent carotid tissue': 32}","{'atheroma plaque': 0, 'adjacent carotid tissue': 1}",True
GDS4513,Clinical outcome of stage UICC II colon cancer patients,Analysis of tumor cells from sporadic stage UICC II colon cancer patients who were treated by elective standard oncological resection but developed relapse during follow-up. Results provide insight into the challenges of constructing molecular signatures predictive for patient outcome.,21465190,GPL570,in situ oligonucleotide,54675,1,53,transformed count,GSE18088,none,data/GEO_v2/datasets/GDS4513.csv,958,disease state,2,"{'no relapse': 40, 'relapse': 13}","{'no relapse': 0, 'relapse': 1}",True
GDS4456,High-risk bladder cancer,Analysis of bladder cancer specimens from a high-risk population of patients who underwent radical cystectomy (Memorial Sloan-Kettering Cancer Center cohort). Results provide insight into the prediction of survival in high-risk urothelial carcinoma of the urinary bladder.,"['22228636', '24486590']",GPL570,in situ oligonucleotide,54675,1,93,transformed count,GSE31684,none,data/GEO_v2/datasets/GDS4456.csv,958,disease state,2,"{'no recurrence/DOD': 54, 'recurrence/DOD': 39}","{'no recurrence/DOD': 0, 'recurrence/DOD': 1}",True
GDS4088,Variable breast cancer tumor sample collection methods,Analysis of breast tumor samples preserved using 2 different RNA stabilization methods (RNAlater or snap freezing) up to 3 hours post tumor excision. Results provide insight into the effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers.,22034635,GPL96,in situ oligonucleotide,22283,1,86,transformed count,GSE25011,none,data/GEO_v2/datasets/GDS4088.csv,958,protocol,2,"{'RNAlater': 66, 'flash frozen': 20}","{'RNAlater': 0, 'flash frozen': 1}",True
GDS4896,Asthma: white blood cells,Analysis of white blood cells from children with severe therapy-resistant asthma and those with controlled persistent mild asthma. Results provide insight into the molecular pathogenesis of these asthma pheontypes.,"['23222870', '25256354']",GPL6244,in situ oligonucleotide,33297,1,54,transformed count,GSE27011,none,data/GEO_v2/datasets/GDS4896.csv,959,disease state,3,"{'mild asthma': 19, 'healthy control': 18, 'severe asthma': 17}","{'mild asthma': 0, 'healthy control': 0, 'severe asthma': 1}",True
GDS4896,Asthma: white blood cells,Analysis of white blood cells from children with severe therapy-resistant asthma and those with controlled persistent mild asthma. Results provide insight into the molecular pathogenesis of these asthma pheontypes.,"['23222870', '25256354']",GPL6244,in situ oligonucleotide,33297,1,54,transformed count,GSE27011,none,data/GEO_v2/datasets/GDS4896.csv,959,disease state,3,"{'mild asthma': 19, 'healthy control': 18, 'severe asthma': 17}","{'mild asthma': 1, 'healthy control': 0, 'severe asthma': 0}",True
GDS4896,Asthma: white blood cells,Analysis of white blood cells from children with severe therapy-resistant asthma and those with controlled persistent mild asthma. Results provide insight into the molecular pathogenesis of these asthma pheontypes.,"['23222870', '25256354']",GPL6244,in situ oligonucleotide,33297,1,54,transformed count,GSE27011,none,data/GEO_v2/datasets/GDS4896.csv,959,gender,2,"{'male': 37, 'female': 17}","{'male': 0, 'female': 1}",True
GDS4404,Facioscapulohumeral muscular dystrophy: bicep and deltoid muscles,Analysis of biceps and deltoids of facioscapulohumeral muscular dystrophy (FSHD) subjects and their unaffected first-degree relatives. FSHD is progressive neuromuscular disorder affecting biceps more severely than deltoid muscles. Results provide insight into molecular basis of FSHD pathogenesis.,22988124,GPL6244,in situ oligonucleotide,33297,1,50,transformed count,GSE36398,none,data/GEO_v2/datasets/GDS4404.csv,959,tissue,2,"{'bicep': 25, 'deltoid': 25}","{'bicep': 0, 'deltoid': 1}",False
GDS4404,Facioscapulohumeral muscular dystrophy: bicep and deltoid muscles,Analysis of biceps and deltoids of facioscapulohumeral muscular dystrophy (FSHD) subjects and their unaffected first-degree relatives. FSHD is progressive neuromuscular disorder affecting biceps more severely than deltoid muscles. Results provide insight into molecular basis of FSHD pathogenesis.,22988124,GPL6244,in situ oligonucleotide,33297,1,50,transformed count,GSE36398,none,data/GEO_v2/datasets/GDS4404.csv,959,disease state,2,"{'facioscapulohumeral muscular dystrophy': 26, 'control': 24}","{'facioscapulohumeral muscular dystrophy': 0, 'control': 1}",False
GDS4837,Never-medicated and medicated bipolar patients: peripheral blood leukocytes,"Analysis of peripheral blood leukocytes from first-episode, never-medicated bipolar disorder (BPD) patients and medicated BPD patients. Results provide insight into a peripheral biomarker profile for BPD that is not induced by medication.",23826396,GPL570,in situ oligonucleotide,54675,1,88,transformed count,GSE46449,none,data/GEO_v2/datasets/GDS4837.csv,958,disease state,3,"{'biploar, medicated': 43, 'control': 39, 'bipolar, first-episode unmedicated': 6}","{'biploar, medicated': 1, 'control': 0, 'bipolar, first-episode unmedicated': 0}",True
GDS4837,Never-medicated and medicated bipolar patients: peripheral blood leukocytes,"Analysis of peripheral blood leukocytes from first-episode, never-medicated bipolar disorder (BPD) patients and medicated BPD patients. Results provide insight into a peripheral biomarker profile for BPD that is not induced by medication.",23826396,GPL570,in situ oligonucleotide,54675,1,88,transformed count,GSE46449,none,data/GEO_v2/datasets/GDS4837.csv,958,disease state,3,"{'biploar, medicated': 43, 'control': 39, 'bipolar, first-episode unmedicated': 6}","{'biploar, medicated': 1, 'control': 0, 'bipolar, first-episode unmedicated': 0}",True
GDS4057,ER-positive/HER2-negative and ER-negative/HER2-negative breast cancer biopsies (MDACC/IGR cohort),Analysis of pre-treatment biopsies from 103 HER2-normal breast cancer patients (ER-positive and ER-negative subtypes) from MD Anderson Cancer Center/Institut Goustave Russy. Results provide insight into molecular mechanisms associated with chemotherapy sensitivity in breast cancer subtypes.,21191116,GPL96,in situ oligonucleotide,22283,1,103,transformed count,GSE22093,none,data/GEO_v2/datasets/GDS4057.csv,958,disease state,6,"{'prechemo T stage 2': 51, 'prechemo T stage 3': 26, 'prechemo T stage 4': 18, 'prechemo T stage NA': 5, 'prechemo T stage 1': 2, 'prechemo T stage 0': 1}","{'prechemo T stage 2': 1, 'prechemo T stage 3': 0, 'prechemo T stage 4': 0, 'prechemo T stage NA': 0, 'prechemo T stage 1': 0, 'prechemo T stage 0': 0}",False
GDS4057,ER-positive/HER2-negative and ER-negative/HER2-negative breast cancer biopsies (MDACC/IGR cohort),Analysis of pre-treatment biopsies from 103 HER2-normal breast cancer patients (ER-positive and ER-negative subtypes) from MD Anderson Cancer Center/Institut Goustave Russy. Results provide insight into molecular mechanisms associated with chemotherapy sensitivity in breast cancer subtypes.,21191116,GPL96,in situ oligonucleotide,22283,1,103,transformed count,GSE22093,none,data/GEO_v2/datasets/GDS4057.csv,958,disease state,6,"{'prechemo T stage 2': 51, 'prechemo T stage 3': 26, 'prechemo T stage 4': 18, 'prechemo T stage NA': 5, 'prechemo T stage 1': 2, 'prechemo T stage 0': 1}","{'prechemo T stage 2': 0, 'prechemo T stage 3': 1, 'prechemo T stage 4': 0, 'prechemo T stage NA': 0, 'prechemo T stage 1': 0, 'prechemo T stage 0': 0}",False
GDS4057,ER-positive/HER2-negative and ER-negative/HER2-negative breast cancer biopsies (MDACC/IGR cohort),Analysis of pre-treatment biopsies from 103 HER2-normal breast cancer patients (ER-positive and ER-negative subtypes) from MD Anderson Cancer Center/Institut Goustave Russy. Results provide insight into molecular mechanisms associated with chemotherapy sensitivity in breast cancer subtypes.,21191116,GPL96,in situ oligonucleotide,22283,1,103,transformed count,GSE22093,none,data/GEO_v2/datasets/GDS4057.csv,958,disease state,6,"{'prechemo T stage 2': 51, 'prechemo T stage 3': 26, 'prechemo T stage 4': 18, 'prechemo T stage NA': 5, 'prechemo T stage 1': 2, 'prechemo T stage 0': 1}","{'prechemo T stage 2': 0, 'prechemo T stage 3': 0, 'prechemo T stage 4': 1, 'prechemo T stage NA': 0, 'prechemo T stage 1': 0, 'prechemo T stage 0': 0}",False
GDS4057,ER-positive/HER2-negative and ER-negative/HER2-negative breast cancer biopsies (MDACC/IGR cohort),Analysis of pre-treatment biopsies from 103 HER2-normal breast cancer patients (ER-positive and ER-negative subtypes) from MD Anderson Cancer Center/Institut Goustave Russy. Results provide insight into molecular mechanisms associated with chemotherapy sensitivity in breast cancer subtypes.,21191116,GPL96,in situ oligonucleotide,22283,1,103,transformed count,GSE22093,none,data/GEO_v2/datasets/GDS4057.csv,958,genotype/variation,3,"{'ER (IHC): -': 56, 'ER (IHC): +': 42, 'ER (IHC): NA': 5}","{'ER (IHC): -': 0, 'ER (IHC): +': 1, 'ER (IHC): NA': 1}",False
GDS4057,ER-positive/HER2-negative and ER-negative/HER2-negative breast cancer biopsies (MDACC/IGR cohort),Analysis of pre-treatment biopsies from 103 HER2-normal breast cancer patients (ER-positive and ER-negative subtypes) from MD Anderson Cancer Center/Institut Goustave Russy. Results provide insight into molecular mechanisms associated with chemotherapy sensitivity in breast cancer subtypes.,21191116,GPL96,in situ oligonucleotide,22283,1,103,transformed count,GSE22093,none,data/GEO_v2/datasets/GDS4057.csv,958,other,3,"{'postchemo: residual invasive cancer': 69, 'postchemo: no invasive cancer': 28, 'postchemo: NA': 6}","{'postchemo: residual invasive cancer': 0, 'postchemo: no invasive cancer': 1, 'postchemo: NA': 1}",False
GDS4206,Pediatric acute leukemia patients with early relapse: white blood cells,"Analysis of WBCs from pediatric B cell precursor (BCP) acute lymphoblastic leukemia (ALL) patients with early, late, or no relapse. For patients with relapsed BCP-ALL, early relapses fare worse than later relapses. Results provide insight into the molecular basis of early relapses in BCP-ALL.",21295523,GPL570,in situ oligonucleotide,54675,1,197,transformed count,GSE13576,none,data/GEO_v2/datasets/GDS4206.csv,958,disease state,3,"{'no relapse': 157, 'early relapse': 26, 'late relapse': 14}","{'no relapse': 0, 'early relapse': 0, 'late relapse': 1}",False
GDS4206,Pediatric acute leukemia patients with early relapse: white blood cells,"Analysis of WBCs from pediatric B cell precursor (BCP) acute lymphoblastic leukemia (ALL) patients with early, late, or no relapse. For patients with relapsed BCP-ALL, early relapses fare worse than later relapses. Results provide insight into the molecular basis of early relapses in BCP-ALL.",21295523,GPL570,in situ oligonucleotide,54675,1,197,transformed count,GSE13576,none,data/GEO_v2/datasets/GDS4206.csv,958,disease state,3,"{'no relapse': 157, 'early relapse': 26, 'late relapse': 14}","{'no relapse': 0, 'early relapse': 1, 'late relapse': 0}",False
GDS4206,Pediatric acute leukemia patients with early relapse: white blood cells,"Analysis of WBCs from pediatric B cell precursor (BCP) acute lymphoblastic leukemia (ALL) patients with early, late, or no relapse. For patients with relapsed BCP-ALL, early relapses fare worse than later relapses. Results provide insight into the molecular basis of early relapses in BCP-ALL.",21295523,GPL570,in situ oligonucleotide,54675,1,197,transformed count,GSE13576,none,data/GEO_v2/datasets/GDS4206.csv,958,disease state,3,"{'no relapse': 157, 'early relapse': 26, 'late relapse': 14}","{'no relapse': 0, 'early relapse': 1, 'late relapse': 1}",False
GDS4296,NCI-60 cancer cell line panel,"Analysis of cell lines from 9 different cancer tissue of origin types (Breast, Central Nervous System, Colon, Leukemia, Melanoma, Non-Small Cell Lung, Ovarian, Prostate, and Renal) from the NCI-60 panel. Results provide insight into molecular mechanisms underlying the various cancer types.","['19584232', '24940735']",GPL570,in situ oligonucleotide,54675,1,174,transformed count,GSE32474,none,data/GEO_v2/datasets/GDS4296.csv,958,tissue,9,"{'melanoma': 26, 'non-small cell lung': 26, 'renal': 23, 'ovarian': 21, 'colon': 21, 'leukemia': 18, 'CNS': 18, 'breast': 15, 'prostate': 6}","{'melanoma': 0, 'non-small cell lung': 0, 'renal': 0, 'ovarian': 0, 'colon': 0, 'leukemia': 0, 'CNS': 0, 'breast': 0, 'prostate': 1}",False
GDS4296,NCI-60 cancer cell line panel,"Analysis of cell lines from 9 different cancer tissue of origin types (Breast, Central Nervous System, Colon, Leukemia, Melanoma, Non-Small Cell Lung, Ovarian, Prostate, and Renal) from the NCI-60 panel. Results provide insight into molecular mechanisms underlying the various cancer types.","['19584232', '24940735']",GPL570,in situ oligonucleotide,54675,1,174,transformed count,GSE32474,none,data/GEO_v2/datasets/GDS4296.csv,958,tissue,9,"{'melanoma': 26, 'non-small cell lung': 26, 'renal': 23, 'ovarian': 21, 'colon': 21, 'leukemia': 18, 'CNS': 18, 'breast': 15, 'prostate': 6}","{'melanoma': 0, 'non-small cell lung': 0, 'renal': 0, 'ovarian': 0, 'colon': 0, 'leukemia': 0, 'CNS': 0, 'breast': 1, 'prostate': 0}",False
GDS4296,NCI-60 cancer cell line panel,"Analysis of cell lines from 9 different cancer tissue of origin types (Breast, Central Nervous System, Colon, Leukemia, Melanoma, Non-Small Cell Lung, Ovarian, Prostate, and Renal) from the NCI-60 panel. Results provide insight into molecular mechanisms underlying the various cancer types.","['19584232', '24940735']",GPL570,in situ oligonucleotide,54675,1,174,transformed count,GSE32474,none,data/GEO_v2/datasets/GDS4296.csv,958,tissue,9,"{'melanoma': 26, 'non-small cell lung': 26, 'renal': 23, 'ovarian': 21, 'colon': 21, 'leukemia': 18, 'CNS': 18, 'breast': 15, 'prostate': 6}","{'melanoma': 0, 'non-small cell lung': 0, 'renal': 0, 'ovarian': 0, 'colon': 0, 'leukemia': 0, 'CNS': 1, 'breast': 0, 'prostate': 0}",False
GDS4296,NCI-60 cancer cell line panel,"Analysis of cell lines from 9 different cancer tissue of origin types (Breast, Central Nervous System, Colon, Leukemia, Melanoma, Non-Small Cell Lung, Ovarian, Prostate, and Renal) from the NCI-60 panel. Results provide insight into molecular mechanisms underlying the various cancer types.","['19584232', '24940735']",GPL570,in situ oligonucleotide,54675,1,174,transformed count,GSE32474,none,data/GEO_v2/datasets/GDS4296.csv,958,tissue,9,"{'melanoma': 26, 'non-small cell lung': 26, 'renal': 23, 'ovarian': 21, 'colon': 21, 'leukemia': 18, 'CNS': 18, 'breast': 15, 'prostate': 6}","{'melanoma': 0, 'non-small cell lung': 0, 'renal': 0, 'ovarian': 0, 'colon': 0, 'leukemia': 1, 'CNS': 0, 'breast': 0, 'prostate': 0}",False
GDS4296,NCI-60 cancer cell line panel,"Analysis of cell lines from 9 different cancer tissue of origin types (Breast, Central Nervous System, Colon, Leukemia, Melanoma, Non-Small Cell Lung, Ovarian, Prostate, and Renal) from the NCI-60 panel. Results provide insight into molecular mechanisms underlying the various cancer types.","['19584232', '24940735']",GPL570,in situ oligonucleotide,54675,1,174,transformed count,GSE32474,none,data/GEO_v2/datasets/GDS4296.csv,958,tissue,9,"{'melanoma': 26, 'non-small cell lung': 26, 'renal': 23, 'ovarian': 21, 'colon': 21, 'leukemia': 18, 'CNS': 18, 'breast': 15, 'prostate': 6}","{'melanoma': 0, 'non-small cell lung': 0, 'renal': 0, 'ovarian': 0, 'colon': 1, 'leukemia': 0, 'CNS': 0, 'breast': 0, 'prostate': 0}",False
GDS4296,NCI-60 cancer cell line panel,"Analysis of cell lines from 9 different cancer tissue of origin types (Breast, Central Nervous System, Colon, Leukemia, Melanoma, Non-Small Cell Lung, Ovarian, Prostate, and Renal) from the NCI-60 panel. Results provide insight into molecular mechanisms underlying the various cancer types.","['19584232', '24940735']",GPL570,in situ oligonucleotide,54675,1,174,transformed count,GSE32474,none,data/GEO_v2/datasets/GDS4296.csv,958,tissue,9,"{'melanoma': 26, 'non-small cell lung': 26, 'renal': 23, 'ovarian': 21, 'colon': 21, 'leukemia': 18, 'CNS': 18, 'breast': 15, 'prostate': 6}","{'melanoma': 0, 'non-small cell lung': 0, 'renal': 0, 'ovarian': 1, 'colon': 0, 'leukemia': 0, 'CNS': 0, 'breast': 0, 'prostate': 0}",False
GDS4296,NCI-60 cancer cell line panel,"Analysis of cell lines from 9 different cancer tissue of origin types (Breast, Central Nervous System, Colon, Leukemia, Melanoma, Non-Small Cell Lung, Ovarian, Prostate, and Renal) from the NCI-60 panel. Results provide insight into molecular mechanisms underlying the various cancer types.","['19584232', '24940735']",GPL570,in situ oligonucleotide,54675,1,174,transformed count,GSE32474,none,data/GEO_v2/datasets/GDS4296.csv,958,tissue,9,"{'melanoma': 26, 'non-small cell lung': 26, 'renal': 23, 'ovarian': 21, 'colon': 21, 'leukemia': 18, 'CNS': 18, 'breast': 15, 'prostate': 6}","{'melanoma': 0, 'non-small cell lung': 0, 'renal': 1, 'ovarian': 0, 'colon': 0, 'leukemia': 0, 'CNS': 0, 'breast': 0, 'prostate': 0}",False
GDS4296,NCI-60 cancer cell line panel,"Analysis of cell lines from 9 different cancer tissue of origin types (Breast, Central Nervous System, Colon, Leukemia, Melanoma, Non-Small Cell Lung, Ovarian, Prostate, and Renal) from the NCI-60 panel. Results provide insight into molecular mechanisms underlying the various cancer types.","['19584232', '24940735']",GPL570,in situ oligonucleotide,54675,1,174,transformed count,GSE32474,none,data/GEO_v2/datasets/GDS4296.csv,958,tissue,9,"{'melanoma': 26, 'non-small cell lung': 26, 'renal': 23, 'ovarian': 21, 'colon': 21, 'leukemia': 18, 'CNS': 18, 'breast': 15, 'prostate': 6}","{'melanoma': 0, 'non-small cell lung': 1, 'renal': 0, 'ovarian': 0, 'colon': 0, 'leukemia': 0, 'CNS': 0, 'breast': 0, 'prostate': 0}",False
GDS4296,NCI-60 cancer cell line panel,"Analysis of cell lines from 9 different cancer tissue of origin types (Breast, Central Nervous System, Colon, Leukemia, Melanoma, Non-Small Cell Lung, Ovarian, Prostate, and Renal) from the NCI-60 panel. Results provide insight into molecular mechanisms underlying the various cancer types.","['19584232', '24940735']",GPL570,in situ oligonucleotide,54675,1,174,transformed count,GSE32474,none,data/GEO_v2/datasets/GDS4296.csv,958,tissue,9,"{'melanoma': 26, 'non-small cell lung': 26, 'renal': 23, 'ovarian': 21, 'colon': 21, 'leukemia': 18, 'CNS': 18, 'breast': 15, 'prostate': 6}","{'melanoma': 1, 'non-small cell lung': 0, 'renal': 0, 'ovarian': 0, 'colon': 0, 'leukemia': 0, 'CNS': 0, 'breast': 0, 'prostate': 0}",False
GDS4761,Breast cancer metastases from different anatomical sites: fine-needle aspiration biopsies,Analysis of breast cancer (BC) metastases from different anatomical sites collected prior to treatment.  The anatomical location of the metastatic lesion is associated with length of survival post-recurrence. Results provide insight into molecular mechanisms underlying BC site-specific metastases.,24287398,GPL10379,in situ oligonucleotide,52378,1,91,transformed count,GSE46141,none,data/GEO_v2/datasets/GDS4761.csv,959,tissue,7,"{'regional lymph node metastasis': 39, 'skin metastasis': 17, 'liver metastasis': 16, 'local metastasis in the breast': 11, 'bone  metastasis': 5, 'lung  metastasis': 2, 'ascite  metastasis': 1}","{'regional lymph node metastasis': 0, 'skin metastasis': 0, 'liver metastasis': 0, 'local metastasis in the breast': 0, 'bone  metastasis': 0, 'lung  metastasis': 0, 'ascite  metastasis': 1}",True
GDS4761,Breast cancer metastases from different anatomical sites: fine-needle aspiration biopsies,Analysis of breast cancer (BC) metastases from different anatomical sites collected prior to treatment.  The anatomical location of the metastatic lesion is associated with length of survival post-recurrence. Results provide insight into molecular mechanisms underlying BC site-specific metastases.,24287398,GPL10379,in situ oligonucleotide,52378,1,91,transformed count,GSE46141,none,data/GEO_v2/datasets/GDS4761.csv,959,tissue,7,"{'regional lymph node metastasis': 39, 'skin metastasis': 17, 'liver metastasis': 16, 'local metastasis in the breast': 11, 'bone  metastasis': 5, 'lung  metastasis': 2, 'ascite  metastasis': 1}","{'regional lymph node metastasis': 0, 'skin metastasis': 0, 'liver metastasis': 0, 'local metastasis in the breast': 0, 'bone  metastasis': 0, 'lung  metastasis': 1, 'ascite  metastasis': 0}",True
GDS4761,Breast cancer metastases from different anatomical sites: fine-needle aspiration biopsies,Analysis of breast cancer (BC) metastases from different anatomical sites collected prior to treatment.  The anatomical location of the metastatic lesion is associated with length of survival post-recurrence. Results provide insight into molecular mechanisms underlying BC site-specific metastases.,24287398,GPL10379,in situ oligonucleotide,52378,1,91,transformed count,GSE46141,none,data/GEO_v2/datasets/GDS4761.csv,959,tissue,7,"{'regional lymph node metastasis': 39, 'skin metastasis': 17, 'liver metastasis': 16, 'local metastasis in the breast': 11, 'bone  metastasis': 5, 'lung  metastasis': 2, 'ascite  metastasis': 1}","{'regional lymph node metastasis': 0, 'skin metastasis': 0, 'liver metastasis': 0, 'local metastasis in the breast': 0, 'bone  metastasis': 1, 'lung  metastasis': 0, 'ascite  metastasis': 0}",True
GDS4761,Breast cancer metastases from different anatomical sites: fine-needle aspiration biopsies,Analysis of breast cancer (BC) metastases from different anatomical sites collected prior to treatment.  The anatomical location of the metastatic lesion is associated with length of survival post-recurrence. Results provide insight into molecular mechanisms underlying BC site-specific metastases.,24287398,GPL10379,in situ oligonucleotide,52378,1,91,transformed count,GSE46141,none,data/GEO_v2/datasets/GDS4761.csv,959,tissue,7,"{'regional lymph node metastasis': 39, 'skin metastasis': 17, 'liver metastasis': 16, 'local metastasis in the breast': 11, 'bone  metastasis': 5, 'lung  metastasis': 2, 'ascite  metastasis': 1}","{'regional lymph node metastasis': 0, 'skin metastasis': 0, 'liver metastasis': 0, 'local metastasis in the breast': 1, 'bone  metastasis': 0, 'lung  metastasis': 0, 'ascite  metastasis': 0}",True
GDS4761,Breast cancer metastases from different anatomical sites: fine-needle aspiration biopsies,Analysis of breast cancer (BC) metastases from different anatomical sites collected prior to treatment.  The anatomical location of the metastatic lesion is associated with length of survival post-recurrence. Results provide insight into molecular mechanisms underlying BC site-specific metastases.,24287398,GPL10379,in situ oligonucleotide,52378,1,91,transformed count,GSE46141,none,data/GEO_v2/datasets/GDS4761.csv,959,tissue,7,"{'regional lymph node metastasis': 39, 'skin metastasis': 17, 'liver metastasis': 16, 'local metastasis in the breast': 11, 'bone  metastasis': 5, 'lung  metastasis': 2, 'ascite  metastasis': 1}","{'regional lymph node metastasis': 0, 'skin metastasis': 0, 'liver metastasis': 1, 'local metastasis in the breast': 0, 'bone  metastasis': 0, 'lung  metastasis': 0, 'ascite  metastasis': 0}",True
GDS4761,Breast cancer metastases from different anatomical sites: fine-needle aspiration biopsies,Analysis of breast cancer (BC) metastases from different anatomical sites collected prior to treatment.  The anatomical location of the metastatic lesion is associated with length of survival post-recurrence. Results provide insight into molecular mechanisms underlying BC site-specific metastases.,24287398,GPL10379,in situ oligonucleotide,52378,1,91,transformed count,GSE46141,none,data/GEO_v2/datasets/GDS4761.csv,959,tissue,7,"{'regional lymph node metastasis': 39, 'skin metastasis': 17, 'liver metastasis': 16, 'local metastasis in the breast': 11, 'bone  metastasis': 5, 'lung  metastasis': 2, 'ascite  metastasis': 1}","{'regional lymph node metastasis': 0, 'skin metastasis': 1, 'liver metastasis': 0, 'local metastasis in the breast': 0, 'bone  metastasis': 0, 'lung  metastasis': 0, 'ascite  metastasis': 0}",True
GDS4761,Breast cancer metastases from different anatomical sites: fine-needle aspiration biopsies,Analysis of breast cancer (BC) metastases from different anatomical sites collected prior to treatment.  The anatomical location of the metastatic lesion is associated with length of survival post-recurrence. Results provide insight into molecular mechanisms underlying BC site-specific metastases.,24287398,GPL10379,in situ oligonucleotide,52378,1,91,transformed count,GSE46141,none,data/GEO_v2/datasets/GDS4761.csv,959,tissue,7,"{'regional lymph node metastasis': 39, 'skin metastasis': 17, 'liver metastasis': 16, 'local metastasis in the breast': 11, 'bone  metastasis': 5, 'lung  metastasis': 2, 'ascite  metastasis': 1}","{'regional lymph node metastasis': 1, 'skin metastasis': 0, 'liver metastasis': 0, 'local metastasis in the breast': 0, 'bone  metastasis': 0, 'lung  metastasis': 0, 'ascite  metastasis': 0}",True
